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ABSTRACT
The aim of this project is to coat halloysite nanotubes (HNTs) with strontium in an ecofriendly, simple, and non-expensive process. These particles, when doped in calcium
phosphate cements (CPC), are predicted to increase the osteoconductive and antibacterial
properties of three dimensional (3D) printed bone scaffolds.
The purpose of the 3D printed bone scaffolds is to assume the same function as
the bones they are replacing but with several additional functionalities. These
biomaterials will have the ability to be resorbed as new bone is formed. Due to inherent
osteogenic factors and antibiotics released from doped HNTs during the reparative
process, it will also provide surgeons with a multi-functional construct for a diverse set of
dental and orthopedic applications. The purpose of the 3D printed scaffolds will be to
provide a microenvironment for normal cells along with the ability to release
antimicrobial, chemotherapeutics or other drugs. The system will also enable growth
factor release.
Material characterization was conducted to confirm the presence of Sr on the
HNTs. Cellular characterizations studies assessed cellular impact and behavior and
included cytocompatibility studies, osteogenic/osteoinductive, and differentiation effects
on pre-osteoblast cells and stromal cells. Material characterization studies included
material strength test of the SrHNT/CPC composites. Based on the results, fabrication
methods in future will be modified as needed to obtain the ideal medical construct.
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CHAPTER 1
INTRODUCTION
1.1 Use of Nanoparticles in Biomedical Engineering
1.1.1

Need of Medicinal Science
There is a rapidly increasing need in medicine for the development of

technologies that can help with the treatment with personalized and specific to individual
patient’s needs which will include replacement of damaged tissues, drug delivery
systems, and biocompatibility. Medicinal science has made advances in types and
availability of drugs that can cure many different ailments. The issues surgeons and
physicians face are the timely release of the drugs, the release of drugs in the required
locations, and the appropriate quantity. In cases of organ or bone replacements surgeries
a more biocompatible material is required which has inherent at antibacterial properties,
patient specific, and easy availability which are cost effective prices.
Many medical conditions need treatments that can be delivered to the specific
area of the ailment. Localized diseases can also be caused by bacteria or fungi. Especially
in cases of implants the risk of infections is high. For example, in cases of knee or hip
replacement surgeries the failure rate can be due to material tear, aseptic loosening,
infection, and instability. For conditions such as advanced osteoarthritis of the knee
where the patients loose knee function and are in extreme pain, total knee arthroplasty is
the most common and effective surgical process. Although, over the years technology has
1
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improved and reduced the cause of failure due aseptic loosening and material wear, the
infection rate on the contrary is increasing [1]. Prosthetics surgeries can cost anywhere
from $5000 to $50,000 [2]. Additionally, the prosthetics failures require hospitalization
and additional procedure which can cost anywhere from $30,000 to $100,000 per patient
[2]. Application of antibiotics can stop or slow bacterial growth and allows body’s
immune system to mobilize.
Cancer is another disease which has the focus of the scientific community. It is a
disease which can be localized or become systemic after it metastasizes. There are many
ways that are now being used to inhibit cancerous cells growth. One such treatment is
chemotherapeutics which involves use of drugs such as 6-mercaptopurine, cytarabine,
gemcitabine, and methotrexate, among many others.
1.1.2

Challenges in Treatment
Challenges in treatment of infections or cancerous diseases include systematic

drug delivery. As of now we have many systematic treatments wherein the drug is
delivered to the entire body. Hence a much larger dose of drugs is needed which can in
turn in then lead to side effects such as hepatotoxicity or nephrotoxicity [3]. If we can
assure a localized treatment with the specific disease treating drug then we can prevent
the negative side effects. Targeted drug delivery can provide more drugs to be effective
for treatment that are found to be toxic or with lower levels of efficiency due to their
distribution in the entire body. Recent researches have shown the efficacy of such
techniques such as carrier proteins, lipid coats or antibodies.
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Biomaterials are latest area of research and medical interest that has led to many
innovations. Materials such as bone cements which were approved in the 1970s are now
improved by inclusion of smart biomaterials. The additional properties to biomaterials
include features like localized drug delivery or sensors to monitor patients’ specific
conditions. These smart materials are described in a new emerging field of
Nanotechnology which is now being increasingly integrated in medical research for
targeted drug deliveries or for creation of biomaterials in increased beneficial and novel
properties [1-5]. A cheaper version of carbon nanotubes are Halloysites (HNT) which is
now showing promise as a novel drug delivery carrier and for creating biomaterials like
calcium phosphate cements (CPC) with improved strength. Through added layers
deposited onto the HNTs, the pattern of released substances can be further controlled,
enabling delayed or inhibited release [5]. These layers can be metal deposits like Gold,
Silver, Copper, Platinum, Strontium etc.
1.1.3

Grand Challenges
Grand Challenges was developed in 2008 by the United States National Academy

for Engineering based on humanitarian needs and technological developments [6]. The
challenge included needs such as affordable solar power, advance health informatics,
engineer of better medicines, access to clean water, etc. Three of these challenges related
to general health needs good health informatics, better medicines, and clean drinking
water. These challenges are interrelated and can lead to better quality of healthcare and
personalized medical care. The creation of nanoparticles without producing any toxic
waste for enhancing the quality of biomaterials would be a novel process integrating
these three challenges and bring positive effect in the quality of medical care.
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1.2

Objectives

This research will have a range of objectives with a single goal of advancing the
properties of biomaterials by optimizing the use of harmful chemicals or products to
make the raw material. The objectives are:
1. To formulate and fabricate green Sr coated HNTs and to evaluate any
cytotoxic effect on pre-osteoblast cells.
2. To formulate and fabricate nano-enhanced calcium phosphate cement and to
evaluate the mechanical, osteoconductive and osteo-inductive properties
3. To evaluate our green SrHNT for antibiotic activity and effective drug
delivery
1.3

Research Need

Metal acetate and metal salts are some of the substances used to deposit metals on
the surface of HNTs which possess a negative charge. many processes use chemicals to
modify the surface for a modified attachment of metal ions [7]. Many coatings are
principally done through a wet chemical process. The majority of these methods are
limited in their use of desired chemicals, due to the polarity of the halloysite [7-9].
Additionally, this constraint in the type of chemicals used frequently involves the use of
additional toxic chemicals in place of greener options, and characteristically necessitates
the use of a significantly longer chemical process to achieve the desired coating. In this
study, we will develop an HNT coating method that is simple, efficient and requires no
post-processing.
We proposed that HNTs can be coated with metal carbonates compounds, as
metal ions donor, and as NMR shift reagents—through a simple breakdown of the salt in
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water. This method will result in a free positively-charged metal ion that can readily bond
to the negatively-charged HNT exterior, resulting in metallic coatings forming on the
HNT surface. In future our coating method may enable greater deposition of coated
material onto these nanotubes for the desired application. Furthermore, the use of
chemical processes using toxic chemicals is not required, thus eliminating exposure to
toxic chemicals and costs associated with the disposal of the resultant chemical waste.
The objective of this study is to improve the anti-infective and mechanical
properties of CPCs by embedding them with Sr coated HNTs to incorporate the
mechanical strength and drug loading capacity of HNTs and the dual action of
osteoconductive, osteoinductive, and antibacterial properties of Sr. We also focused on
using SrHNT as cancer and antibacterial drug carriers.

CHAPTER 2
BACKGROUND

2.1 Nanoparticles
We are now in the age of medicinal and technological revolution. From 3D
printing a car, silicon chips, to nanotubes we have come a long way. Medicine has also
seen that exponential progress which can be seen as increased survival rate and the higher
average death age in Homo sapiens aka modern man. In spite of all the advancements we
still have cases of infection after surgeries in sterile and aseptic environment. An addition
understanding in additive manufacturing and recent advances in nanotechnology is vital
to comprehend their capabilities in the area of medicine. Nowadays nanoparticles are
used as vehicles for drug delivery. HNTs are used as biosensors and drug carriers.
Addition of nanoparticles and HNTs to polymeric matrices has also led to improved
mechanical strength [1].
2.1.1

Halloysite
Halloysite nanotubes (HNTs) are a form of aluminosilicate with the chemical

formula Al2Si2O5(OH)4.nH2O [2-4]. They are a naturally occurring clay mineral with a
tubular structure and an inner diameter of 10-15 nm and the outer diameter of 50-70 nm,
with average linear dimensions of 50-70 nm 1 and are chemically similar to kaolinite [5].
It takes millions of years of hydrothermal process and weathering that result in HNTs
from kaolinites [8-9]. Named after Omalius D’Halloy, HNTs was extensively used in the
6
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ceramics industries. HNT was first discovered around 18th century [10-11]. The unique
crystalline structure was identified after the invention of X-ray analysis and gained
popularity in the field of nanotechnology due to its tubular structure. HNTs have been
researched extensively as a delivery system for different chemicals, antibacterial and
anticancer drugs, as an adsorbent, and as a nanofiller to improve mechanical and thermal
properties, etc. [11-12].
HNTs are structured two layered nanotubes in a dehydrated state forms a hollow
lumen. The thickness of the layers depends on the state of hydration such as during
hydrated state it is 10Å and 7Å during dehydrated state. The silica layer is on the outer
side of the tube and the alumina layer is on the inner lumen surface as seen in Figure 2-1.
The inner surface of the lumen is positively charged with an external negative surface
[14]. The outer surface has low hydroxyl density which is the target for attachment of
metal ions for specific applications such as modified surfaces using surfactants, coupling
agents, electrostatic adsorption or layer by layer coatings [14-15]. Substances with an
overall positive charge such as antibiotics, growth factors, and hormones can be loaded
inside the lumen [15-16].
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Figure 2-1: Structure of halloysite showing the inner hydroxyl (-Al-OH) surface.

2.1.2

Halloysite Structure Related to Release of Bioactive Agents
The difference in the chemical composition on the different sides of HNT makes

it unique among other nanotubes. Both inner and outer surfaces have different ionization
and dielectric properties. Both sides can be modified selectively and have many
beneficial applications. One of the properties of the HNT based on the charge of the
lumen and its diameter is the capability to encase macromolecules including proteins
drugs, and Di oxy ribonucleic acid (DNA) [18]. The lumen of HNT is wettable with high
capillary force allowing the filling of lumen. The loading of DNA in HNTs probably
occurs in the lumen as its cationic and DNA is anionic comparatively [19]. Such loaded
HNTs can be used for external applications. The diameter of the lumen makes it a good
container for protein molecules. Since the lumen has a positive charge the proteins with
high isoelectric points can be efficiently be loaded in the lumen. In some cases, research
have shown non-specific protein and lipid adsorption [20]. HNTs easily adsorbs
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polyallyamine hydrochloride, chitosan, etc. [21]. Due to biocompatibility and high
loading capacity, HNTs make good carriers as drug delivery vehicles.
2.1.3

Drug Delivery Strategies Using HNTs
There are two ways to administer drugs by conventional methods, orally and

through injection.
Insulin administration is affected by its digestion by proteolytic enzymes, speedy
degradation, or inactivation along with poor permeability results in low availability [22].
These are suggested to be overcome by loading it in HNTs. Research has shown that
drugs such as furosemide, dexamethasone, and niferadine show a pattern of slow release
when loaded in HNTs [23-25]. The hollow cylindrical lumen of HNT when loaded by
vacuum cycling results in extended drug delivery over time [25]. Due to pressure the
chemicals are loaded in the lumen but these chemicals can be coated externally also. For
the drug release the desorption of the active agent from the outer surface and ends of the
tubes occurs first, then the drugs inside the lumen are released more slowly through pore
diffusion. Research has shown that loaded HNT show a 5-10% initial burst release
followed by a slower release rate [26]. Through added layers deposited onto the HNTs,
the pattern of released substances can be further controlled, enabling delayed or inhibited
release [25-26]. HNTs used as filler enhances the mechanical properties of various
biomaterials. When these HNTs are coated with metal then their ability to increase the
material properties for the biomaterial also tends to show an increase.
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2.2 Metal Nanoparticles
Metal nanoparticles have been commonly used in the labeling and tracking of
stem cells [27]. Magnetic nanoparticles (MNPs) are currently being explored as a means
for manipulating stem cell commitment, in particular, for the regeneration of bone and
cartilage to combat various orthopedic diseases [28]. Gold and silver nanoparticles have
seen considerable interest as nanoparticles for a range of biomedical applications in the
areas of microbial resistance, anti-cancer, drug delivery, and bioengineered reparative
tissues.
2.2.1

Iron Oxide Nanoparticles
Iron oxide nanoparticles, as seen in non-regenerative studies, have been use the

labeling and tracking of stem cells [29-30]. Mechanical stimulation (through mechanotransduction) can be used to facilitate stem cell proliferation, differentiation into different
lineages, and migration of stem cells bound to RGD receptors on the surface of
osteoblasts and with applied cyclical magnetic stimulation over a 3-week period [29-30].
Osteoblasts upregulated osteopontin, a key bone cell marker, and indicator of osteoblast
differentiation, maturation, and matrix mineralization [30]. A recent interesting study
supports the potential of iron oxide MNPs to promote osteogenic differentiation of human
bone marrow-derived using the MAPK pathway [31].
2.2.2

Silver Nanoparticles
Silver nanoparticles possess several unique characteristics including a potent and

broad-spectrum level of antimicrobial activity [31]. AgNPs showed enhanced
proliferation and osteogenic differentiation of various animal-derived MSCs and
promoted fracture healing [33-34]. As an implant coating, AgNPs have also been
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effective in promoting bone tissue formation and mineralization on various surfaces [3435].
2.2.3

Gold Nanoparticles
Gold nanoparticles (AuNPs) have also attracted much attention recently in

biomedicine for uses in anti-cancer applications, drug delivery, and regenerative
medicine. This is ascribed to its relatively low toxicity compared to other NPs [36].
AuNPs have been shown to regulate MSC differentiation various cell types, such as
osteoblasts [37-38], cardiocytes [39], and neuronal cells [40]. AuNPs have also been
used to direct stem cell differentiation. AuNPs act on MSCs to activate the Wnt/βcatenin, ERK/MAPK, and p38 MAPK pathways, resulting in the activation of the
transcription factors for the osteogenic differentiation [40].
2.2.4

Magnesium Nanoparticles
Magnesium (Mg) is a divalent ion found abundantly in the body and plays an

important role in many cellular processes. It is used in human body as activator of
enzymes, regulation of neuromuscular activities and central nervous system, synthesis of
protein, myocardial contraction and regulation of temperature. Mg is biocompatible and
biodegradable and can play a potential role as an implant material [41]. Mg in alloys have
been shown to be an excellent candidate for vascular stents, biodegradable orthopedic
implants and hyperthermia [42]. Mg has certain advantages over gold nanoparticles such
as lower density (1.7 g/cm3) and hence easier loading on the target site [41]. This density
almost mimics the density of human bones. Due to the abundance of this metal, it can be
cost effective for clinical use. When MSCs are cultured in presence of magnesium,
research has observed a decrease in calcium influx and intracellular calcium
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concentration [42]. Mg has been shown to have a positive effect on cell coverage of H9OCT4ESCs [44]. Osteoporosis and osteopenia have been associated with low
concentration of Mg. Since Wnt/β-pathways and activation of Notch signaling are related
to bone marrow MSCs osteogenesis, Mg can enhance proliferation in these MSCs and
herby increase osteogenesis [45]. Integrins play an important role in activation of
intracellular pathway and cell differentiation. Research showed that magnesium improved
the attachment of synovial MSCs to osteochondral defect through integrin α3β1 [46].
Increase in concentration of Mg can also stimulate gene expression of TRPM7 to
promote osteoblasts proliferation [47].
2.2.5

Zinc Nanoparticles
Zinc has multitude of physiological functions in human body. Zinc and alloys

using zinc are progressively promising biomaterials for orthopedic and dental
applications [48]. The use of Zinc alloys as biomaterials for making scaffolds mimicking
mammalian bone. Zinc leads to an increased ECM mineralization in MSCs and there is a
concentration dependent regarding SMCs [48]. Studies have shown that cells preferred
Zn ions on the interface of biomaterials rather than it being in diffused state when
measured as an expression of Zn transporters (ZnT1 and ZIP1) [50-51]. Further research
on zinc supplementation in osteogenesis in MC3T3-E1 cells showed increased collagen
deposition and mineralization [51]. Zinc phosphate has shown potential anti-bacterial
properties and helped in preventing bacterial colonization, when loaded on barrier
membranes. For osteoblastogenesis these actions can be regulated by zinc through the
TGF-β/Smad signaling pathway [52]. The increased osteogenic differentiation and
mineralization Zinc makes for an excellent candidate as coatings on implants to promote
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integration. Adipose derived (AD) MSCs can differentiate into chondrocytes, osteoblasts
and neuron like cells. Supplementation by Zn can increase AD-MSCs proliferation and
neutrite growth. ERK1/2, BDNF, and JMK are some of the potential molecules involved
in the action and regulation of Zn [53]. Wang et al. (2007) reported that Zn2+ decreased
adipocytic cell formation in mouse bone marrow stem cells leading to mineralization,
osteoblast proliferation, bone formation, and inhibition of bone resorption [54].

2.3 Strontium
Strontium (Sr) nanoparticles have been established as metal ions that can lead to a
significant improvement in the biological and mechanical properties of many polymers.
The growing interest of strontium and nanoclays as implants is based on the effects of Sr
on cells to induce osteogenic and osteoinductive properties. Sr is now used in dental
implants and orthopedic coatings. Sr may also lead to bone healing process after further
remodeling [55].
One of the primary methods to advance the properties of biomaterials is by adding
trace quantities of metal elements. These elements play a significant role in enhancing the
biological response, increase in mechanical properties, drug release, and control of the
degradation rate of biomaterials. There is an increased interest developing over the years
for the use of Sr as the additional element. Information about Sr gained momentum in the
mid-19th century with an early review published in 1964 [56]. The signaling of vascular
endothelial growth factor is essential for stem cell commitment. Research found that Sr
triggered the secretion of these growth factors which were associated with RhoA/Rac 1
activation and thereby repressing adipogenesis and activating osteoblastogenesis in
gravity induced alteration of cell commitment [57-58]. Sr treated MSCs was reported to
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increase phosphorylation of MAPK ERK1/2 and p38 along with osteogenic
differentiation [59]. One of the members of the MAPK family is the ERK1/2
(Extracellular signal related kinase) involved in cellular response to apoptotic promoting
signals [59]. Strontium ranelate in lower doses can enhance hASC osteogenic
differentiation but higher doses can cause hASC apoptosis by activating ERK signaling
pathway [60]. This information lay a solid foundation for Sr containing scaffolds for use
in bone engineering.
2.3.1

History of Strontium
Strontium was first discovered in a mine in 1790 and isolated in 1808 [56]. A soft

silver-white chemical element with an atomic number of 38, strontium (Sr) is an alkaline
earth metal which is not hazardous when occurring in a naturally stable form [61]. It
readily oxidizes to form an oxide yellowish in color. It comprises only 0.02-0.03% of the
earth’s crust and is widely available. It occurs naturally on earth and found mainly as
carbonate (SrCO3) and sulfates. Sr in plants acts as a growth stimulant and in Chorella
plant Sr can replace Ca requirements [61]. Sr is not a highly essential element in our body
but can prevent caries in rats when administered in moderate amounts. Research has
shown that Sr taken as Sr ranelate increase bone Ca and reduces fracture percentage in
osteoporotic patients [62-62]. Data on the requirements of Sr in bones is scarce and more
research is needed in that aspect of bone repairs, since research has shown Sr is the only
trace metal that correlated with bone compression. Excessive amounts of Sr or Sr
overdose causing toxicity in humans have not been reported yet. However, if high
quantities of Sr are delivered intravenously, it has shown to result hypocalcemia due to
renal secretion of Ca [64-65]. Research has shown that dietary digestion of large amounts
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of Sr varies in hens and pigs [66-67]. Till date only known genotoxic carcinogen is
Strontium chromate [68-69]. Human body differentiates the use between Ca and Sr based
on the body functions for example mammary secretions, renal absorption, and
gastrointestinal absorption [70]. Though Sr absorption decreases with age, consumption
of Vitamin D promotes the intestinal absorption. This difference in the absorption rates of
Sr and calcium can be attributed to the smaller size of Ca atom. In recent times Sr is
being investigated as pharmacological substance in cells and organs mimicking the
actions of Ca although the stimulated response is comparatively weaker [70]. Research
showed that Sr ions were effective in insulin mediated glucose cell uptake when there
was a Ca and Mg ions deprivation to a certain extent [68].
2.3.2

Strontium versus Calcium
Sr can form divalent cations in biological fluids and has protein binding capacity

in plasma or serum similar to calcium. Sr falls after calcium in the periodic table and
shares many similar properties. It is softer than calcium with a lower melting point of
777oC and a boiling point of 1655oC comparatively [72]. Sr forms coprecipitates such as
anhydrite and calcite in presence of calcium and a slightly higher pH [72-73]. The density
of Sr is 2.64 g/cm3 and is very close to calcium with a density of 1.54 g/cm3 [73]. The
amount of Sr in human skeleton is about 0.035% of the total Ca content [66]. RadioSr
does not stay in the body for a long time and is cleared immediately after it is injected.
By the process of diffusion Sr transverses, the walls of the Harvesian capillaries and
reaches the extracellular fluid of bones. Due to its similarities with calcium, Sr is
incorporated in bone repair as Sr2+ (ions) are bone-seeking and can stay in the body for a
long time [74]. The response of signaling principle and metabolic pathways for calcium
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follow Sr albeit the effects are weaker but have almost similar protein binding capacity
[74]. The important difference in the response of Sr and Ca to accumulation in the bone is
due to the fact the amount of Sr is less compared to Ca. Sr has been shown to have a dual
effect of the development and inhibition of degradation by enhancing osteoblast and
inhibition of osteoclast activities. Researchers have proposed that Sr turns on the
signaling pathway associated with calcium-regulated bone metabolism by acting on the
calcium-sensing receptor (CaSR) of bone forming cells [75]. It has been shown that under
the effect of Sr there is a decrease in inhibitors of Wnt-pathway and increase in β-catenin
expression marking an increase transcription of osteogenic factors and prostaglandin
expression [76]. Some animal studies show that Sr can substitute Ca in some
physiological process like blood clotting and muscle contraction although to a lesser
extent. It may be due to its smaller size, Ca is transported more easily than Sr in lactation,
renal excretion, placental passage, and gastrointestinal absorption [74]. The toxicity of Sr
in human body is not very pronounced [68-69], hence supervised administration of Sr is
possible without any deleterious effect on physiological functions and human organ
systems. The capacity of CPC to host ions like Sr2+ can lead to bone cell response over
the generally used growth factors have an impact on bone healing therapeutic methods of
modern regenerative medicine.

2.4 Metal Coating Procedures
Halloysite is an abundant natural nanomaterial with deposits in France, China,
Belgium, and New Zealand. Due to the ease of availability, functionalization, and defined
structures, HNT based nanocomposites is now being researched for many decades owing
to their tubular structure, hydrophobicity, ion exchange, and physiochemical properties
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[77]. HNTs have also been used for catalytic [77], antibacterial [78], magnetic [79],
electrical [80], and energy storage applications [75-78]. Recent research has also focused
on interfacial relationship of these nanoparticles. Based on those results surface
modification of HNT is gaining prominence as a host for different functional compounds
such as drugs and bio-molecules. Most research on metal deposition on HNT focus on
transitional metals such as Ag, Au, Pt, Ru, and Pd. Some of the methods used are
Solvothermal method, Dry sintering, Silanization, etc.
2.4.1

Solvothermal Synthesis
Solvothermal is a system dependent process method is a chemical reaction

occurring at high temperatures and pressures which changes the fundamental properties
of the solvent [81]. Since density, ionic product, viscosity, dielectric constant, thermal
conductivity, and heat capacity are temperature and pressure dependent, the solvent
properties can be adjusted based on these two parameters [81-82]. For example, when the
temperature increases the dielectric constant decreases resulting in a solid phase
precipitate of ionic species. Similarly, the Sol-gel process involves a wet chemical
method where formation of a sol (inorganic colloidal suspense) and the gelation of the sol
in a gel (continuous liquid phase) to form a 3D network structure [83]. Sol-gel is
performed at low temperatures and an acid or base is used to catalyze the reaction which
can alter the hydrolysis and condensation [83-84]. The specific interaction between the
drug, adsorption solvent and the sol-gel interface determine the deposition of the kind of
molecules adsorbed on the HNTs [84]. The advantages of solvothermal process is that it
is a one step process, it has pH sensibility, and high photocatalytic activity [85]. The
disadvantages of such a method is the use of acids, bases or other harsh chemicals as
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solvent or catalyst, specific requirements for oven for creating an atmosphere of high
temperature, it is time consuming, and not cost effective.
2.4.2

Silanization of HNT
Aminofunctional silane can be applied to nanoparticles to improve adhesion thus

control and increase the amount of metal on the surface. Due to the absence of chemical
bonding, the naturally treated HNT have low adhesion to certain metals. Modified HNT
surface with an organo-silane finds uses in fields of anticorrosion, enzyme
immobilization, and nanocomposite materials [86]. In silanization method the surface of
HNT is modified by using γ-aminopropyltriethoxysilane (APTES) which leads to
Pd/NH2-HNT as seen in Figure 2-2 [75].
APTES is a toxic substance (MSDS health score=3) The chemical is carefully
used under hood since it creates fumes which are destructive to the upper respiratory tract
and mucous membranes. This compound acts on the kidneys, liver, and nerves hence the
use of APTES is done under extreme precaution.

Figure 2-2: Palladium (Pd) nanoparticles deposited on the surface of halloysite
nanotubes (HNTs) modified with γ-aminopropyltriethoxysilane (APTES) to produce
Pd/NH2-HNTs nanocomposites.
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The advantages of this method are that the surface property of the NH2-HNT is beneficial
in improving the dispersion and loading of Pd which can be uniformly distributed with
smaller particle size. This can lead to higher catalytic activity of the product. The
disadvantages of this method are it requires very specific binding which uses very toxic
and harsh chemicals. It is a cumbersome and expensive process.
2.4.3

Dry Sintering Method
For coating of the HNT surface, a layering method is commonly used to achieve

the desired coatings onto the exterior surface, using the inherent charge differential
between the layers of the nanotubes as the basis for these coatings [88]. In Dry sintering
method, metal acetylacetonates—compounds primarily are used in the synthesis of
nanoparticles, metal catalysts, and as NMR shift reagents. This method is capable of
thermally decaying the metal acetylacetonate molecules, resulting in a free positivelycharged metal ion that readily bonds to the negatively-charged exterior of the HNT [86].
Most metal acetylacetonates degrade completely at 300 ◦C, outgassing acetone and
carbon dioxide and leaving behind positively-charged metal ions. Due to the negativelycharged outer lumen of the halloysite, these metal ions should readily bond to the outer
surface, allowing for a one-step sintering coating [86].
The advantages of this process are it’s a simple process with simpler fabrication
conditions, environmentally safe, and does not require the use of any caustic material.
The disadvantage of this method is that it is not very cost effective as it requires an
energy source for operating the oven to keep it going at 300 ͦ C.
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The objective of this research was to come up with a single step low cost,
environmentally friendly and safe method to coat Sr on HNTs without producing any
toxic waste or the use of any harsh chemicals.

CHAPTER 3
BONE CEMENT

3.1 Bone Cement
Today in orthopedic surgeries the most widely used biomaterials are metal
implants and bone grafts. Chronic health conditions, such as osteoporosis and bone
fractures and injuries, can be treated with surgery only and medications can help only
provide so much relief. This method of using tissue engineering methods and implants to
restore bio-functionality is defined as regenerative medicine [87]. The best examples of
these are the allografts and autografts of bones. The availability of the right size,
appropriate shape, with desired bio-functionality, antibacterial properties,
biocompatibility and biodegradability is scarce [88].
The biomaterials used in most orthopedics surgeries are bone grafts, metal
implants, and bone cements. The intended role of these biomaterials is to restore the
functionality of the body part where they are inserted. Bone is capable of repair small
injuries but those severe injuries caused by disease like gout, osteoporosis, rheumatoid
arthritis, osteo sarcoma, and bone fractures can be repaired by surgeries and medicine
only. This restoration of body functions by implants, bone grafts, allografts, or autografts
is a good example of Regenerative Medicine [89]. It is often rare to find the biomaterial
of right size and shape and results in additional post-operative complications and care. In
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such cases bone cements are usually employed in treating joint replacement surgeries and
fractures. For example, Arthroplasties surgeries involve complete or partial joint
replacements [90]. Such surgeries use industrial built metal implants which are
supported and held in place by the surrounding bones and bone cement. This supporting
cement is under flexural and shear forces as seen in Figure 3-1.

Figure 3-1: Illustration of total hip replacement implant and various forces acting on the
cement.

In surgeries like kyphoplasty, vertebroplasty, and compression fractures in the
vertebral column, using percutaneous injection the bone cement is injected into the
fractured bone [91].
The most widely used commercial bone cement is polymethylmethacrylate
(PMMA) [92]. The usual application method is by dry mixing of the bone cement with
the drugs and then administered to the body. These cements have an exothermic setting
temperature ranging from 70 -120oC during implantation [92-93]. These cements have
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other disadvantages such as the addition of antibiotics decreases the mechanical strength
and are released quickly but not completely [94]. The methyl methacrylate monomers
damage the surrounding tissue as they are toxic in nature and are released at the bone
cement interface [94].
Polymeric materials loaded with HNTs have shown an increase in mechanical and
material stability and performance [95]. Along with the material properties, these HNTs
can enhance the chemical, biological and thermal properties. In recent times HNTs have
been used to impart high surface reactivity, increase surface area, mechanical strength,
toughness, and thermal stability at a relatively low cost [95-97]. Biomaterials in contact
with bone have a fundamentally strong interface to support the mechanical integrity of
the supported bone [98]. The mechanical and biological properties of biomaterials like
CPCs can also be enhanced using metal coated HNTs.
3.1.1

Calcium Phosphate Cement
CPC in different companies use different forms and ratios of calcium and

phosphate salts such as calcium monobasic phosphate, anhydrous calcium diphosphate,
calcium diphosphate dihydrate, calcium tri phosphate, tetra calcium phosphate, etc. The
cement is usually prepared by mixing two of such calcium salts and making it to a paste
by adding a setting liquid. Different researches and companies use various setting liquid
such as water, disodium phosphate, saline solution, and chitosan [98]. The calcium and
phosphate salts precipitates as crystals of dicalcium phosphate or hydroxyapatite and
along with the setting liquid sets into a hard cement mass. Here we use tetra calcium
phosphate and di calcium phosphate. The structural formula is seen below in Figure 3-2.
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Figure 3-2: Chemical structure of the two calcium phosphate salts used to make CPC in
this lab.

Depending on the salts used and the final product the cements are classified in two
categories Brushite or Apatite. The difference in these categories is that Apatite, result in
HA, are stronger and degrade slowly. Whereas Brushite has anhydrous calcium phosphate
as the setting result and it degrades faster comparatively [99].
3.1.2

Chitosan
For our research, we used chitosan as the setting liquid based on the established

protocol by previous research conducted in this lab by Uday et al (2017). It is a
biodegradable, osteoconductive, and biocompatible polysaccharide, promotes cell
attachment and proliferation hence is widely use in bone and tissue engineering.
Processed crustacean shells produce chitin which is further processed by deacetylation to
produce chitosan. It is a polymer of glucosamine as seen in Figure 3-3.

25

Figure 3-3: Chemical structure of chitosan showing the monomer unit of D-glucosamine

Addition of chitosan in CPC as a setting liquid improves the flexural and
compressive strengths [99], also decreases the setting time [98]. The addition of Chitosan
reduces or prevents CPC from precipitating or washing out [98]. This property is called
cohesiveness or anti washout [98].
3.1.3

Addition of Nanoparticles
CPC are osteo-conductive and biocompatible but with low mechanical properties.

Many fillers or polymers can be added to the paste to enhance the mechanical properties.
CPCs have numerous advantages over PMMA such as durability, formability, low
shrinkage, dense, and a porous nature [94-98]. Research is now being directed to enhance
the mechanical and biological properties of CPCs. The addition of HNTs and other
nanoparticles have been used as additives and have resulted in improving the mechanical
stability of the material and also serving as a drug carrier [94]. Currently, CPCs used in
regenerative medicine and orthopedic surgery is restricted to non-load bearing regions
such as craniofacial and maxillofacial surgeries only [88]. There is a high demand for
developing osteoconductive and osteogenic CPC which have a good load bearing
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capacity for 3D printing bones for transplantations [94]. The use of strontium for bone
regeneration has garnered significant interest over the past years due to its beneficial
properties in treating bone loss associated with osteoporosis [100].
Since Sr and calcium share many chemical similarities, incorporating Sr coated
HNTs (SrHNTs) in bone structure will result in a strengthening of the bone and induces
bone formation by osteoblasts while reducing bone reabsorption by osteoclasts along
with anti-bacterial and drug loading capacity.

CHAPTER 4
DRUG LOADING

4.1 Effective Drug Loading
The worldwide escalation of bacterial resistance to conventional medical
antibiotics is a serious concern for modern medicine. High prevalence of multidrugresistant bacteria among bacteria-based infections decreases effectiveness of current
treatments and causes thousands of deaths. New improvements in present methods and
novel strategies are urgently needed to cope with this problem. Owing to their
antibacterial activities, metallic nanoparticles represent an effective solution for
overcoming bacterial resistance. However, sometimes metallic nanoparticles are toxic,
which causes restrictions in their use. Recent studies have shown that combining
nanoparticles with antibiotics not only reduces the toxicity of both agents towards human
cells by decreasing the requirement for high dosages but also increases their bactericidal
properties. Combining antibiotics with nanoparticles also restores their ability to destroy
bacteria that have acquired resistance to them. Furthermore, nanoparticles tagged with
antibiotics have been shown to increase the concentration of antibiotics at the site of
bacterium-antibiotic interaction, and to enable binding of antibiotics to bacteria [101].
Several strategies have used in implants such as surface modification or coating with
antimicrobial agents to prevent bacterial colonization and biofilm formation [102-103].
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The antibiotics used to treat bone infections are given intravenously or orally, through
antibiotic-releasing bone cement, or collagen sponges [104-105]. Antibiotics currently
used suffer from systemic toxicity, short half-life, and may lead to an increase in
antibiotic resistance [106]. Collectively, these approaches have shown limited
effectiveness due to the lack of site specificity, uncontrolled release, and ineffective
control over microbial growth. Metal nanoparticles are gaining interest as they are
effective in controlling pathogenic bacterial and microorganism growth due to targeted
delivery [104].
4.1.1

Metal Nanoparticles
Antimicrobial effect of heavy metals has been known and utilized since centuries.

Silver was used in wound care and as self-sanitizing cutlery similarly copper has been
used in brass for storing water, gold has been used in dental fillings, arsenic has been
used in treatment of syphilis [106]. The use of metal can be attributed for causing
damage to bacterial cell by production of reactive oxygen species, protein denaturing,
and cell membrane damage [107]. Additionally, metals such as silver, copper etc. exert
toxicity at low concentrations which is nontoxic to mammalian cells. Reduction of the
metal particle size amplifies the toxicity even at low level and in this regard,
nanotechnology holds great promise. Silver, copper, zinc, titanium oxide nanoparticles
have shown increased efficacy against prokaryotes [108]. Metal nanoparticles find utility
in various potential medical applications as biofouling surfaces, implants, topical agents
etc., they have the potential to act as a structural reinforcer, stimulate angiogenesis,
promote extracellular matrix synthesis, inhibit bone resorption and many have an
inherent antimicrobial activity [109]. Multiple factors affect the success of antimicrobial
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device including osseointegration, degradation, anti-biofouling, and angiogenesis
capability [110]. Incorporation of several metallic nanoparticles having an inherent
antimicrobial activity such as silver [110], strontium [111], zinc oxide [112], and copper
[113] have been shown further help improve implants by exhibiting anti-biofouling
effects.
Metal nanoparticles at higher concentrations exhibit bactericidal effect but
toxicity to eukaryotic cell lines as well. Several studies have reported that combinations
of the metal nanoparticles can lower the lethal concentration level [114]. Combination of
silver, copper, zinc, nanoparticles has shown to exhibit synergistic antimicrobial activity,
which can be attributed to increased prokaryotic cell permeability [115-116]. Further,
metals when combined with antibiotics, have shown similar augmented antimicrobial
effect [117-118]. Metal nanoparticles have been combined with support surfaces such as
polymers, ceramics, clay nanoparticles [119]. Metal nanoparticles deposited on
halloysite outer surface have also shown enhanced antimicrobial activity [120].
Hydroxyapatite (HA), a widely studied calcium phosphate and bioactive glass suffer
drawbacks such low biodegradability and mechanical qualities making them impractical
candidates for such applications and require structural modification. These shortcomings
can be improved by blending/modification with metal nanoparticles that act as a
structural reinforcer, stimulate angiogenesis, promote extracellular matrix synthesis,
inhibit bone resorption, and importantly have an inherent antimicrobial activity.
The successful regeneration of bone requires a ‘complete package’ consisting of
three integral components: osteoprogenitor cells, osteogenic factors, and
osteoinductive/osteoconductive scaffolds [121]. Inherent in any bioengineered design
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are these requirements in the scaffold structure: interconnected porosity, adequate
mechanical properties, and stimulating healing by inducing chemotaxis, proliferation,
and osteoblast differentiation [122-123]. A significant issue with the use of growth
factors is specific delivery to the target site and in the required amounts. Many
antibiotics or chemotherapeutics are delivered systemically, but their efficacy is limited
due the insufficient quantities of drug reaching the affected site [124]. Previous studies
have shown that HNTs can stimulate chemotaxis, proliferation, and osteoblast
differentiation [125-127], and can be doped with antibiotics, chemotherapeutics, and
steroids, and 3D printed into various devices [128]. HA incorporated with strontium
[113], zinc [114], silver [119], iron [118], and titanium [112] nanoparticles respectively
show improved tensile properties after their addition. Metal nanoparticles including
copper [115], strontium [113], and cobalt [118] have also shown strong angiogenic
effects.
4.1.2

Antibiotic Delivery
Antibiotics can be delivered either systematically or locally. Local

administration has many advantages over systemic such as lower risk of toxicity, low
cost, and high concentrations of antibiotics at the targeted site [129]. Loading metal
coated HNT can lead to a systemic release locally. It can reduce the drawbacks of
systemic delivery and also development of resistant strains. Local delivery of drugs has
applications in orthopedics and dentistry. To prevent a cytotoxic effect of the drug it
must have a critical concentration of 8-16 μg/ml to 100 μg/ml [129-130]. CPC have
been loaded with vancomycin and gentamicin to reduce bone infections in orthopedics
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surgeries [131]. Antibiotics have been added to the cement in solid or liquid phase [132134].
4.1.3

Use of Gentamicin
Gentamicin sulphate is one of the most commonly used antibiotics in

cranioplasty. It is highly efficient against infections, although it has shown to have
negative influence on cell proliferation [135]. It is important to understand the
concentration of use of gentamicin. Gentamicin is an aminoglycoside antibiotic, as seen
in Figure 4-1, which is not absorbed by the gut when it is administered orally [136].
Hence it is administered through intravenous, or intramuscular injection. It can cause
dose related negative side effects such as irreversible hearing loss or nephrotoxicity
[135].

Figure 4-1: Schematic representation of Gentamicin sulphate.

It is impertinent to ensure that the patient does not receive high dose in an instant.
Aminoglycosides act on some gram-positive and gram-negative bacteria by inhibiting
protein synthesis. Inside the bacterial cell gentamicin binds to the 30S subunit of the
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ribosome resulting in the misreading of mRNA causing interruption in normal protein
synthesis [137]. Gentamicin is given in slow dose three minutes by bolus injection or
over thirty minutes via intravenous injection [138]. The dose also depends on the body
and body mass index of the patients. Gentamicin is easily cleared by the kidneys [138].
But it is important to ensure the healthiness of the renal system before administration of
this drugs.
4.1.4

Methotrexate
Methotrexate was developed in 1940s as a cancer drug where it effectively stops

malignant cells from proliferation and blocks the access of the cells for folate needed by
the such cells to survive [139]. The chemical representation of Methotrexate is seen in
Figure 4-2.

Figure 4-2: Schematic representation of Methotrexate

More recent use of Methotrexate is for treating rheumatoid arthritis and other
types of inflammatory arthritis [140]. The dose concentration of this drug is between 10
to 25 mg/week whereas the dose for certain types of cancer is hundreds of times higher
[140].
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4.1.5

Strontium and Drug Loaded HNT
Based on the promising data that demonstrated the synergistic effects of

antimicrobial agents with nanoparticles, we believe that this combination is a potential
candidate for more research into treatments for antibiotic-resistant bacteria and other
disease. We used this knowledge in creating a complete delivery package that includes
antibiotics, or cancer medication to support bone tissue regeneration directly to the
infected part by loading SrHNTs with the drugs by vacuum loading.

CHAPTER 5
METHODS

5.1 Materials
5.1.1

To Prepare Sr Coated HNTs
We ordered HNTs from Sigma Aldrich and coated with Sr by adding the HNTs

and Strontium carbonate (SrCO3) from Sigma Aldrich in same quantities in distilled
water as seen in Figure 5-1. The even distribution and preventions of clot formation was
done using a sonicator. The reaction mixture (Rm) was sonicated at regular intervals for a
duration of 30 minutes for 3 days. The Rm was exposed to three different temperatures.
One set was kept at room temperature (25 ͦ C), another in incubator (60 ͦ C) and the third
one was microwaved till boiled.

Figure 5-1: Schematic representation of the process to make Green SrHNT
The precipitate obtained was washed in citric acid (pH=4) to remove excess CO32ions and water washed 3 times. The precipitate was collected and dried.
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5.1.2

Calcium Phosphate Cement
Two calcium salts were used calcium phosphate dibasic anhydrous (DCPA-

CaHPO4) from Sigma Aldrich, St Louis, MO and Tetra calcium phosphate (TTCPCa4(PO4)2O) was ordered specifically from CaP Biomaterials, E. Troy, WI, for a specific
particle size. Chitosan Oligosaccharide Lactate was brought from Sigma-Aldrich, St
Louis, Mo. The ratio of the mixture was the one used from previous work which showed
the best compressive strengths and anti washout property.
For all the tests four groups of samples were made.
Group 1: CPC
Group 2: CPC with 1% wt HNT, SrCO3, and SrHNT each
Group 3: CPC with 5% wt HNT, SrCO3, and SrHNT each
Group 4: CPC with 10% wt HNT, SrCO3, and SrHNT each

5.2 Material Testing
5.2.1

Compression Test
Cylindrical shaped specimen was made of 12 mm x 6 mm (Length x Diameter) in

accordance with the ATSM F-451 standards. Since this project was an extension for the
previous work done in this lab, these standards were chosen. The specimens were tested
using CellScale UniVert testing equipment with a load speed of 1 mm/min.
5.2.2

Flexural Testing
Cuboid specimen was made of 65 x 10x 4 mm was made using a 3D printed mold

to maintain the size and shape of the specimens and subjected to a 3-point bend test. Load
speed was 1 mm/min using CellScale UniVert testing equipment. Flexural strength of the
CPCs was tested using the following formula.
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3𝐹𝐿
=𝜎
2𝑏𝑑𝑥𝑑
Where σ is the Flexural strength, F is the peak force, L is the distance between the
3 points, b is the width of the sample, and d is the height of the sample.
5.2.3

Scanning Electron Microscope (SEM)
Sample preparation for SEM was used to analyze the surface of CPCs. S4800

Field Emission SEM, HITACHI was used. The high magnification attained by SEM
allowed for a close comparison of the surface morphologies of the HNTs, SrHNTs and
the four groups of CPCs.
5.2.4

Energy Dispersive Spectroscopy (EDS)
SEM EDS was performed for HNTs and SrHNTs with the help of EDAX

dispersive X-ray analyzer attached to the HITACHI S-4800 SEM to evaluate the
elemental composition and weight percentage of Sr on the HNTs. EDS was done at
distance of 15mm with an acceleration voltage of 15kV and the spectra was analyzed
using the EDAX Genesis software.
5.2.5

X-Ray Diffraction (XRD)
XRD for HNT and SrHNT was done using Bruker D8 Venture diffractometer

(Brunker, Karlsruhe, Germany). The scan speed and step size used was 2s and 0.02 ͦ . The
diffraction patterns were recorded using a Philips PW 1710 X-ray powder diffractometer
over 2Ɵ within 3 ͦ and 85 ͦ.
5.2.6

Fourier Transformation Infrared (FT-IR) Spectroscopy
FT-IR was done of HNT, SrCO3, SrHNTs discs and the discs of groups 1 and 4,

to analyze the composition of the powders using the Attenuated Total Reflection (ATR)
method. IR Spectroscopy is usually used for qualitative identification of organic and
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inorganic compounds. This method is used for checking presence of functional groups in
organic compounds. ATR method was used as it’s a more efficient method to analyze a
sample to give a more accurate result and has low signal to noise ratio. The discs were
prepared by the same procedure.
5.2.7

Multi BET/ Pore Size Testing
Pore size is very important aspect of tissue engineering especially for bones. The

large pore size can result in smaller surface areas which can reduce space for cell
attachment. Very small pore size will inhibit the migration of cells towards the center and
also limit the diffusion of nutrients or removal of waste. The pore size of the different
CPCs samples was measured for 1 gm of samples in NOVA 2200 surface area and pore
size analyzer. The measurements were done for 0.200 gm first. Since the measurements
are more accurate for large quantities the measurement was repeated 2 more times for 1
gm of samples.
5.2.8

Bio-Degradability Test
Stimulated body fluid (SBF) is a fluid created in the lab that mimics the ion

concentrations approximately equal to human blood plasma. SBF has been used for
invitro assessment to measure biodegradability of many materials. The samples from the
four groups of CPC were tested for bio-degradability by comparing the weight reduction
over a period of six weeks. The discs were soaked in SBF and stored at 37 ͦ C. The media
was changed every two days. The weight of all the samples was measured as dry
samples, after soaking, and every week for six weeks.
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5.3 Cell Culture
All cells came cryopreserved from ATCC. Cryovials were thawed and allowed to
equilibrate in a water bath, all the cells were cultured in 25 cm2 tissue culture flask and
incubated at 37°C under humidified 5% CO2 and 95% air. Pre-osteoblast and BSC cells
were incubated in complete alpha-MEM and Dulbecco’s Modified Eagle medium
respectively, containing 10% FBS and 1% penicillin. Sub-confluent cells were passaged
with 0.25% trypsin, collected by centrifugation, suspended in cell culture medium and
cultured at a 1:4 split into 25 cm.2 tissue culture flasks. Cell count was same in all the
wells during each testing. The cells went through passage four before use.
5.3.1

Cell Culture and Staining
Mouse pre-osteoblast cell lines MC3T3-E1 (ATCC® CRL-2593™) were

obtained from ATCC (Manassas, VA.). These cells were used to evaluate the cytotoxicity
and proliferation of all the samples. Proliferation tests for four groups of CPCs was dome
on day 1, 7, 14, 21, and 28. Mouse bone marrow stromal cells (BSCs) (ATCC® Crl12424™ was used. Both the cells lines were seeded in 48 well plates which had 40 mg of
the samples on each well. Both cells lines were used to analyze for collagen, acidic
mucopolysaccharides and ALPase activity. Osteoconductive tests was done on Day 1, 7,
14, and 21 and osteoinductive tests was done on Day 1, 7, 14, 21, and 28 days. The
control was just cells. Cell culture and lab plastics were obtained from MidScientific, St.
Louis, Mo. Alpha minimal essential medium (α-MEM) and Dulbecco’s DMEM were
obtained from GIBCO Invitrogen, Grand Island, NY. Fetal bovine serum and penicillin
were purchased from Phenix Research Products (Candler, NC). TryplE, an animal-free
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trypsin substitute, and Trypan blue were obtained from GIBCO Invitrogen, (Grand
Island, NY).
5.3.2

Cytotoxicity Testing
Live/Dead as a means for estimating the cell viability after exposure to HNTs,

SrHNTs and the Four groups of CPCs were assessed by MTS assay. Cells were seeded
into 48-well plate at a concentration of 1 X 105 cells/ well and cultured for 24 hours.
Different amount of pure HNTs or functionalized HNTs were added into cell culture
plates (0, 25 and 50 μg/ml). 40 μg of the four groups of samples was added to each well
of the 48 well plate. The assay was performed using Biotium cytotoxicity kit. The
live/dead assay was performed on day 1,3, and 7. The fluorescence images were taken
using Olympus Florescence microscope fitted with a Nikon camera
5.3.3

Cell Proliferation Assay
Cell proliferation ability affected by HNTs and SrHNTs were assessed by MTS

assay. Different amount of pure HNTs or SrHNTs were added into cell culture plates (0,
25 and 50 μg/ml). Proliferation assay was conducted on day 1, 3, and 7 days. 40 mg of
the four groups of samples was added to each well of the 48 well plate. Proliferation
assay was conducted on day 1, 7, 14, 21, and 28 days. Cells were seeded into 48-well
plate at a concentration of 1 X 105 cells/ well and cultured for 24 hours. 40 μl MTS stock
solution were added to each well and cultured for 2 hours at 37°C in darkness. 200ul of
supernatant of each sample were transferred to 96-well plates and read absorbance values
at 490nm by microplate reader.
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5.4 Cell Staining
5.4.1

Picosirus Red Staining
Media was removed from the wells and washed with Phosphate Buffer solution

from Dulbecco’s (PBS)to quantify the collagen content. The cells were fixed with 95%
ethanol for 10 minutes. The cells were washed again with PBS twice. The staining kit had
two solutions, the Picosirus stain (PRS) and acetic acid 0.5% (AA). These cells were then
stained with PSR for 60 minutes and then washed with AA to remove excess staining. 7%
v/v aqueous solution of Glacial acetic acid was used for de-staining. To quantify, the destaining liquid was measured for staining concentration using Thermo Scientific
spectrophotometer at 490 nm.
Since PRS stain showed maximum absorbance at that wavelength. This staining
procedure was also used on Pre-osteoblast cells and the images were taken over a period
of 28 days under contrast microscope.
5.4.2

Alcian Blue Staining
Cells were fixed as mentioned earlier. Alcian blue (AB) stain was added and

removed after 10 minutes. Excess stain was washed with PBS and De-stained by 7%
Glacial acetic acid. The detained supernatant was used to measure the optical density at
405 nm in Thermo Scientific spectrophotometry.
5.4.3

ALPase Assay
Alkaline phosphatase is an enzyme characteristic of osteoblast cells, the presence

of which shows the ability of the cells to break down phosphate groups from their
substrates. ALPase acts on 5-Bromo-4-chloro-3-indolyl phosphate/Nitro blue tenzolium
(BCIP/NBT) substrate to give a purple stain. The cells were fixed by the method
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mentioned above and the dye was added for 15 minutes. The supernatant was quantified
through measurement of its optical density at 405 nm in Thermo Scientific
spectrophotometer.
5.4.4

Alizarin Red Stain
This stain is used to detect the calcium present in the wells. The pre osteoblasts

cells with the four groups of CPCs was stained with alizarin red stain (Alizarin
monosodium sulfonate from Matheson Coleman & Bill Manufacturing Chemists,
Norwood, Ohio). The cells were fixed by the method mentioned before and washed 3
times with water and images was taken under Fluorescence microscope in bright image
every seven days for four weeks.

5.5 Drug Loading
Drugs were loaded in the HNTs, SrHNTs and HNTSr by vacuum method, washed
with water after loading to remove externally attached Gentamicin as seen in Figure 5-2.

Figure 5-2: Process of loading gentamicin in HNT, SrHNT and HNTSr. HNTSr was
HNTs loaded with gentamicin and then located with Sr.
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5.6 Bacterial Growth Rate Study
The antibacterial properties of HNT, SrHNT and gentamicin loaded HNTs,
SrHNTS and HNTSr (These HNTs were loaded with the drug and then coated with Sr)
on Escherichia coli (ATCC 35218) and Staphylococcus aureus (ATCC BAA-1026) was
evaluated.
5.6.1

Micro Titration Method
The effect of HNT, SrHNT and gentamicin loaded HNTs, SrHNTS and HNTSr

was evaluated for their effect on bacterial growth rate and drug release using the microtitration method since they were in powder form. The starting concentration of the sample
was 10 μg/ml. It was serially diluted in 4 consecutive wells. Three colony cultures of
bacterial was chosen to get 3 repetitions of the tests. Bacteria was grown on Luria-Bertani
(LB) broth. The test was conducted in Miller Hilton broth.
5.6.2

Kirby Bauer Disk Susceptibility Test
In this method HNT, SrHNT and gentamicin (concentration 1g/10ml) loaded

HNT, SrHNT, and HNTSr in CPC samples was made. The paste was then made into
discs 6 mm in diameter, same as the size of the standard gentamicin discs. The discs were
impregnated on a Mueller-Hilton agar plate which had the lawn of E. coli and S. aureus
bacteria individually. The inoculation of the bacteria was done when the culture showed
an absorbance of 0.08-0.1 at 630 nm which corresponds to 1 to 2 x 108 CFU/ml. The
plates were then incubated at 37 ͦ C for 18 hours. The standards of testing of antibiotics
affects are an accepted method by the U.S. Food and Drug Administration and was
followed accordingly. The zone of inhibition around the disk was measured and noted.
The method was done using cultures from 3 different colonies.
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5.6.3

Drug Release Testing

5.6.3.1

Pre-osteoblast Cells and E. coli
To test the effectiveness of drug release in a cellular environment infected with E.

coli, this test was performed. A 48 well plate was first seeded with pre-osteoblast cells
(3.14 x 105/ml) for two days. After which the media was changed and fresh media was
added. The media had 2% Trptic soy broth/nutrient media for bacterial growth. The
gentamicin loaded HNT, SrHNT, and HNTSr was added to the wells in 3 different
concentrations 1, 0.1, and 0.01 mg/ml. The bacterial culture was added in accordance
with the standards. The bacterial culture had an absorbance of 0.08 at 630 nm. The plates
were incubated at 37 ͦ C for 24 hours after which the absorbance. Live/dead assay, and
proliferation assay was done to measure the effects of drug release on bacterial growth in
pre-osteoblast cells.
5.6.3.2

Mammalian Osteosarcoma Cells
The drug release was also tested on CRL 2836 mouse osteosarcoma cells. The

cells (2.76 x 105/ml) were plated in a 48 well plate and incubated for two days. The
media was changed and methotrexate loaded HNT, SrHNT, and HNTSr was added to the
wells in 3 different concentrations 1, 0.1, and 0.01 mg/ml. The plates were incubated at
37 ͦ C for 3 days after which the Live/dead assay and proliferation assay was done to
measure the effects of drug release on bacterial growth in cancer cells.

5.7 Statistical Analysis
Statistical analysis was performed using Microsoft Excel Analysis ToolPak plugin
and Origin 9.6. All experiments were done in triplicate, and one-way analysis of variance
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(ANOVA) with p < 0.05 as the significance level was utilized for statistical analysis.
Statistically significant data was reported (p < 0.05), and all the results were reported as
mean ± standard deviation (p < 0.05, n=3) unless otherwise specified.

CHAPTER 6
RESULTS AND DISCUSSION

6.1 Project 1: Coating HNTs with Strontium
6.1.1

Surface Topography
The coating of Sr on HNT was done at three different temperatures. The SEM

images were taken to confirm the coatings and also confirm the best temperature for
coatings of the HNTs. The images of the HNTs coated by Sr at room temperature, 60 ͦ C,
and microwaved were analyzed for successful coating and can be seen in Figure 6-1.

A

B

C

D

Figure 6-1: SEM images of A) HNT and Sr coated HNTs B) At oven C) Microwaved D)
At room temperature.
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As the SEM images show the coating of Sr was successful in all the three
exposures. Since the coatings were observed at room temperature the experiment was
conducted three more times to observe the consistency of the method. There is an
irregular but complete coating of Sr on the HNTs as seen in Figure 6-2. HNTs by default
have a smooth exterior. The SrCO3 hydrolyze into Sr2+ and CO32- ions when water is
added to the salt. Since HNT has a negative exterior surface due to the presence of OH-, it
attracts the positively charges ions to form a bond which can be either a Vander Waal’s
bond or a weak ionic bond. In both cases the Sr2+ gets attached to the surface of the
HNTs.

A

B

C

D

Figure 6-2: SEM images of SrHNTs of multiple attempts (A-D) showing sediment like
formation on the surface of HNT.
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The bond between Sr2+ and HNT surface was not weak since citric acid (pH=4) was used
as a wash to remove excess of CO32- ions and the remaining of SrCO3 salt. The images
were taken after the citric acid was washed away with water. Citric acid was used as a
substitute for lemon juice (pH=2.5) to maintain consistency of the pH level during the
washes. Different lemons possess slightly different properties which causes procedural
variations each time they are used. At lower pH, citric acid is a harmless and non-toxic
chemical which provides an environmentally safe option to remove the excess unwanted
ions introduced during the formation of SrHNTs. SEM images showed that there was a
successful layering of Sr on HNTs which formed a bond strong enough to remain stable
even after exposure to acid with pH of 4.
6.1.2

EDS Report
To ensure the presence of Sr on the HNTs EDS was performed which is a

quantitative analysis of the chemical elements present in a selected region. As seen in
Figure 6.3. The EDS -SEM analyzed the chemical characterization of the region selected
on HNTs and SrHNTs as seen in red outline in Figure 6-3 A and B respectively.
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A
Figure 6-3 A: The quantitative elemental analysis of the area selected on (A) HNT and
(C) SrHNT show the wt% of carbon [C], aluminum [Al], silicon [Si], oxygen [O] of
HNT. The peak of Si is clearly seen

B
Figure 6-3 B: The quantitative elemental analysis of the area selected on (A) HNT and
(C) SrHNT show the wt% of carbon [C], aluminum [Al], silicon [Si], oxygen [O] and
Strontium [Sr] of SrHNT. The two peaks of Sr are the two peaks are the two shells K and
L of Sr.

The quantitative analysis of the different elements present on HNT and SrHNT
elemental report clearly show the presence of Sr on Sr coated HNTs. The same peak of Si
is not visible in the reports of SrHNT and the value is 0 as the K shell peak of Si overlaps
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the L shell peak of Sr. All the samples of HNTs and the average of the qualitative
compositional information of HNTs and SrHNT was put in Figure 6-4.
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Figure 6-4: The graph of quantitative wt% of the elements present in HNT and SrHNT
namely K shell of C, Al, Si, O, and Sr where n=5. The error bars are the standard
deviation of the samples.

As seen in the graph the presence of the element Sr was confirmed by EDS giving
value to the method of coating SrHNT. The method of EDS can be used to determine the
presence of chemical element and it also gives an estimate of their abundance, the
accuracy of this method can be affected by various other factors such as overlapping
peaks. For more accurate estimation of the sample composition further tests were done.
6.1.3

FTIR -ATR
To confirm the presence of Sr on HNTs FTIR-ATR was conducted on the HNT

samples, SrCO3 and SrHNT which provided the molecular fingerprint to compare the
samples. The high spectral resolution data of the three samples can be seen in Figure 6-5.
Light in the infra-red region was absorbed corresponding to specific bonds present in the
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samples. The absorption peaks on the inverted y-axis depicts the percent of transmittance
of radiation of the particular sample.

Figure 6-5: FTIR-ATR analysis of (-----) SrCO3 (-----) HNT and (-----) SrHNT (n=3)
SrCO3 has a strong peak at 1400 and 800 cm-1 depicting the -CO group. The
position of carbonyl group depends on the function of the molecule. The position of
carbonyl group here is characteristic to SrCO3. For HNT there is a distinct peak at 1040
cm-1 showing the -SiO group. There is the peak at 900 cm-1 showing the presence of
AlOH bond. Band peaks at 3100-3700 cm-1 are caused by -OH groups. The OH bond
usually appears These peaks are distinctive factors of recognizing HNTs. For SrHNT
there are combination of peaks at 3100-3700 cm-1, 1400-800 cm-1, and 3600-400 cm-1. IR
radiation effect in such a way that higher the frequency higher the wavelength. SrHNT
showed a distinct presence of Sr on HNT in the sample. FTIR results also showed that the
coating could be a combination of Sr2+ ions and SrCO3. Since there are peaks showing
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the CO bond along with the presence of HNT absorption peaks. The validity of SrCO3
FTIR results were confirmed based of previously published data. Stronger the peaks on
SrHNT more confirmed is the presence of the HNT and SrCO3.
6.1.4

XRD
To further confirm the presence of Sr on HNT XRD was used as some bonds that

are not visible through FTIR. Since the wavelength of X-rays is on atomic scale, this was
the final tool to measure the accuracy of composition of SrHNTs. XRD was done to
compare the diffractions of HNT, SrCO3, and SrHNT as seen in Figure 6-6. The XRD
peaks seen in the Figure 6-6 were produced by the interference of a monochromatic
beam of X-ray scattered at specific angle from each set of lattice plane in the sample

Counts (X-Ray Intensity)

measured.

Figure 6-6: XRD graph image of HNT, SrCO3 and SrHNT.

As seen in the Figure 6-6 HNT has distinctive peaks at lattice structure 001, 110,
and 002. There is a distinct peak of SrCO3 at 111. Since the HNT is covered by Sr2- The
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crystal structure of SrHNT shows reduced peaks of HNT but the distinctive characteristic
peak of SrCO3. This showed that SrHNT did have Sr present either in ionic form to form
bond with the free hydroxyl group and through the attachment of SrCO3 to the surface of
HNTs.
6.1.5

Cytotoxicity Test for SrHNTs
Having confirmed the presence of Sr on HNTs it was important understand the

cytotoxic effect of Sr on biological cells. Literature shows that Sr in moderate mounts can
be beneficial to the physiological systems. Live dead assay was performed to confirm the
quantity of SrHNT that would allow the cells to grow unhindered. Two different
concentration was tested on pre-osteoblast cells and the results are seen in Figure 6-7.
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Figure 6-7: Live dead assay of two concentrations, 25 and 50 μg/ml of HNT and SrHNT
showing the live cells in green on top image and dead cells in red on the image below for
day 1, 3, 5, and 7.

As seen Figure 6-7 HNTs showed a good viability of day 1 (95%), 3 (95.6%), 5
(95.67%), and 7 (95.9%) at lower and 1 (88.8%), 3 (88.9%), 5 (84.8%), and 7 (97.1%) at
higher concentrations. Although the number of cells on day was affected by high
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concentrations of HNT. SrHNTs show a good cell viability on day 1 (88.2%), 3
(91.47%), 5 (92.5%) and 7 (97.135) at lower concentration whereas at high concentration
the affect was derogatory by day 5 (55.3%) and almost no live cells are seen by day 7. To
get a quantitative analysis of the live-dead assay ImageJ app was used to count the cells
and the graph was plotted using those numbers as seen in Figure 6-8. Data is missing for
Day 7 for high concentration of SrHNT as the cells were visibly absent in the
fluorescence image but the ImageJ app calculated the viability at 90%.

Figure 6-8: Graph showing the quantitive values of cell count calculated (live cell/total
cell count). Grey and green lines depict HNT and SrHNT respectively. High
concentration lines are depicted by marked lines. Error bars are standard deviation where
n=3.

As seen in the Figure 6-8, high concentrations of SrHNT were not conducive for
cell growth implying SrHNT did not favor cell growth at 50 μg/ml. Although no research
has been published to show the absence of any toxic effect by Sr but for the use of
SrHNT in biological systems it was necessary to predict the concentration that could be
used without hindering cell growth. This test showed that the use of Sr should be limited
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to 25 μg/ml. In order to ensure the cytocompatibility of the right amount of SrHNT, this
information was important, also for further testing where SrHNTs was imbedded in CPCs
and will be useful for further use in other biomedical applications.
6.1.6

Proliferation Assay
Since biological systems are a moving system due to blood flow, this test was

conducted to see the effect of exposure of pre-osteoblast cells to different concentrations
of HNTs and SrHNTs for a period of seven days and the values was plotted in a graph as
seen in Figure 6-9. The cells were exposed to the different concentrations of the two
samples for 48 hours. On y-axis the absorbance of the cells is seen at 630 nm. Higher cell
count showed higher absorbance.

Figure 6-9: Graph showing proliferation of pre-osteoblast cells after exposed to two
different concentrations 25 and 50 μg/ml of HNT and SrHNT for day 1, 3, 5, and 7. Grey
and green lines depict HNT and SrHNT respectively. High concentration lines are
depicted by marked lines. Error bars are standard deviation where n=3.

As the graph shows that exposure to low (0.341 Å) and high (0.439 Å)
concentrations of SrHNTs did not affect the cell proliferation. But exposure to high
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concentration (0.09 Å) of HNTs had a derogatory effect on proliferation when compared
to low concentration (0.472 Å). As seen in Figure 6-9 there was no emerging damage
was seen by exposure of cells to high concentration of SrHNTs. The rate of proliferation
was higher in case of SrHNTs. Cells after being exposed to SrHNTs proliferated, whereas
the cells exposed high concentrations of HNTs showed a decline in proliferation. It is not
completely understood at this point about the behavior of the cells in such a manner.
Further tests must be conducted to determine the effect of exposure on cells and for a
long period of time. The assay however proved that in presence of SrHNTs the cells did
not alter their proliferation rate by a large number and could reach the rate of
proliferation almost as the control cells over time.
6.1.7

Bacterial Growth Rate
The effect of HNT, SrHNT and gentamicin loaded HNT, SrHNT, HNTSr was

tested for a period of 48 hours on the growth rate of three nosocomial bacteria
Escherichia coli (Figure 6-10), Staphylococcus aureus (Figure 6-11), and
Staphylococcus epidermis (Figure 6-12) separately. SrHNT lowered the growth rate in
the case of all three bacteria when compared to HNT at a low concentration of 5 μg/ml.
This showed that HNT had an inherent property has some bactericidal or bacteriostatic
effect on nosocomial bacteria which was enhanced when HNT was coated with Sr. When
HNTs was loaded with gentamicin it was released efficiently to inhibit the growth of
bacteria. When SrHNT was loaded with HNT the cap of the cylindrical HNT was not
closed with Sr covering and the antibiotics was released and hence there is no bacterial
growth seen. When HNT was loaded and then coated with gentamicin, the graphs show
no bacterial growth showing the effective release of antibiotics.
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Figure 6-10: This graph shows the growth rate of E. coli over 24 hours. Bacterial growth
was tested based on CSLI microtitration method. The data is average of 3 different
colonies. In this graph the concentration of sample of HNT, SrHNT, Gentamicin loaded
HNT*, SrHNT*, and HNTSr* was 5μg. Total reaction mixture was 100 µl. Error bars are
standard error of the mean.

Figure 6-11: This graph shows the growth rate of S. aureus over 24 hours. Bacterial
growth was tested based on CSLI microtitration method. The data is average of 3
different colonies. In this graph the concentration of sample of HNT, SrHNT, Gentamicin
loaded HNT*, SrHNT*, and HNTSr* was 5μg. Total reaction mixture was 100 µl. Error
bars are standard error of the mean.
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Figure 6-12: This graph shows the growth rate of S. aureus over 24 hours. Bacterial
growth was tested based on CSLI microtitration method. The data is average of 3
different colonies. In this graph the concentration of sample of HNT, SrHNT, Gentamicin
loaded HNT*, SrHNT*, and HNTSr* was 5μg. Total reaction mixture was 100 µl. Error
bars are standard error of the mean.

SrHNT has some inherent quality that lowers the bacterial growth rate.
Coating HNTs with Sr before or after loading with drugs does not hinder its drug release
capacity making then good carriers. The SrHNTs can serve as carriers for many drugs
and when embedded in biomaterials such as CPC or hydrogels, this will be a better way
to release the drugs in the implant as research shows that loading drugs in carriers slows
the rate of release and for prolonged duration of time. Since SrHNT itself lowers bacterial
growth rate, it will help reduce the chance of infection on the implant site.

6.2 Project 2: Embedding SrHNT in CPC for Bone Regeneration
6.2.1

FTIR-ATR
The setting product of all the four groups was chitosan. To evaluate the detection

of HNT and SrHNT FTIR was used. Figure 6-13 compares the IR spectra of CPC with
10% HNT, SrCO3, and SrHNT each. Three samples from each group was analyzed and
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the average was plotted. Peaks seen at 900-1200 cm-1 is due to PO43- groups. Peak at
1400-1300 cm-1 are characteristics of CO32- groups in hydroxyapatite. Peaks around 3000
cm-1 are characteristics of -OH groups. In case of SrHNTs the peaks of -OH group is
smaller it is theorized that the free Sr ions are attaching to the -OH groups.

Figure 6-13: FTIR spectra of (-----) CPC HNT (-----) CPC SrHNT and (-----) CPC
SrCO3, n=3.

6.2.2

Cytotoxicity Test
This test was done to evaluate if there was any cytotoxic effect of SrHNT and

CPC combination for all the different percentages. For Group 2 (Figure 6-14 A and B
showed the live and dead cell images respectively. Figure 6-14 C showed the cell
viability calculated for the images via ImageJ), Group 3 (Figure 6-15 A and B showed
the live and dead cell images respectively. Figure 6-15 C showed the cell viability
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calculated for the images via ImageJ), and Group 4 (Figure 6-16 A and B showed the
live and dead cell images respectively. Figure 6-16 C showed the cell viability calculated
for the images via ImageJ). The cell viability after 7 days increased to match the
population of control cells as seen in the figures of images given below. There is increase
in cell viability from day 1, 3, 5 to day 7 with all the groups as seen in green. The dead
cells are seen in red. The sample also took up the color of the reagent and appear red and
green in the live dead images. 1%, 5%, and 10% HNT, SrCO3, and SrHNT in CPC was
not cytotoxic to pre-osteoblast cell line and did not reduce the cell viability. The graphs
for cell viability was plotted for all the groups, Figure 6-14 C, Figure 6-15 C, and
Figure 6-16 C for 1%, 5%, and 10% respectively. Higher cell viability meant higher ratio
of live cells over the total number of live and cell count. One-way Anova was calculated
for all the groups and there was no significant difference between the groups where value
of p was 0.05.

Figure 6-14 A: Live pre-osteoblast cells seen in green over a period of 1 week with 40
mg of 1% HNT, SrCO3, and SrHNT in CPC respectively.
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Figure 6-14 B: Dead pre-osteoblast cells seen in red over a period of 1 week with 40 mg
of 1% HNT, SrCO3, and SrHNT in CPC respectively.
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Figure 6-14 C: Cell viability graph for CPC and CPC with 1% HNT, SrCO3, and
SrHNT. Error bars show the standard deviation. n=3.
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Figure 6-15 A: Live pre-osteoblast cells seen in green over a period of 1 week with 40
mg of 5% HNT, SrCO3, and SrHNT in CPC respectively.

Figure 6-15 B: Dead pre-osteoblast cells seen in red over a period of 1 week with 40 mg
of 5% HNT, SrCO3, and SrHNT in CPC respectively.
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Figure 6-15 C: Cell viability graph for CPC and CPC with 5% HNT, SrCO3, and
SrHNT. Error bars show the standard deviation. n=3.

Figure 6-16 A: Live pre-osteoblast cells seen in green over a period of 1 week with 40
mg of 10% HNT, SrCO3, and SrHNT in CPC respectively.
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Figure 6-16 B: Dead pre-osteoblast cells seen in red over a period of 1 week with 40 mg
of 10% HNT, SrCO3, and SrHNT in CPC respectively.
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Figure 6-16 C: Cell viability graph for CPC and CPC with 10% HNT, SrCO3, and
SrHNT. Error bars show the standard deviation. n=3
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6.2.3

Proliferation Assay
After testing for cytotoxicity, it was important to confirm that the presence of

CPC with SrHNT will not hinder or inhibit cell proliferation. This test was conducted for
a period of one month as usually the implants starts to biodegrade by that duration and
the wound starts to heal. Adding SrHNTs in CPC was not cytotoxic and did not prevent
cell proliferation as seen in graphical representation in Figures 6-17 A, B, and C show
SrHNTs in 1%, 5%, and 10% wt in CPC respectively. Higher absorbance showed higher
cell number. There is trend for all the groups where the cell counts show and increase
from day 1 to 3 and there is a decrease on Day 5. This may be due to cell saturation.
There is an increase on day 7 after which there is a decline during day 14 and 21. This
may be due to increase in space after day 5 when the cells reached saturation and
maturation creating more space which led to cell count increase on day 7 after which
there was little probability since the cell proliferation had crossed the threshold
saturation. Although the cell number did not match the control cells, this can be attributed
to lack of space for cells to adhere in presence of CPC crystals which protruding arears
which would make cell adherence difficult. After a period of 28 days there is a decline in
cell number in control cells also and can be explained due to lack of space in the 48 well
plates after cells grew to the point of space saturation. One-way Anova calculated for all
the groups showed no significant difference between the groups. The highest mean
calculated was for control cells. This test showed that embedding CPC with HNT, SrCO3,
and SrHNT did not prevent cell proliferation. SrHNT 10% in CPC showed better
proliferation than just control cells. Graphs show that HNT and SrCO3 individually add to
the properties of SrHNT when they are tested in moderate amounts.
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Figure 6-17 A: Cell proliferation measured as absorbance at 630 nm for control cells,
CPC, and CPC with 1% HNT, SrCO3, and SrHNT individually. n=3
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Figure 6-17 B: Cell proliferation measured as absorbance at 630 nm for control cells,
CPC, and CPC with 5% HNT, SrCO3, and SrHNT individually. n=3
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Figure 6-17 C: Cell proliferation measured as absorbance at 630 nm for control cells,
CPC, and CPC with 10% HNT, SrCO3, and SrHNT individually.

6.2.4

Alcian Blue Stain
To evaluate the synthesis of ECM molecules other than collagen, this staining

procedure was used to identify acidic mucopolysaccharides. Figure 6-18 A (Mouse
stromal cells and Figure 6-18 B (pre-osteoblast cells) show the graphical representation
of alcian blue staining for a period of 28 and 21 days respectively. Higher absorbance
showed higher synthesis of acidic mucopolysaccharides. For stromal cells there was an
overall increase till day 14 and then there is a gradual reduction on day 21 and 28. This
may be due the fact the cells further differentiated, developed further or broke down to
simpler compounds. The peak of mucopolysaccharides was reached in two weeks. 10%
SrHNT in CPC showed the maximum absorbance over the period of 28 days. Adding
SrHNT to CPC added it value to help stromal cells to differentiate in mucopolysaccharide
cells. One-way Anova showed no significant difference with highest average in 5% and
10% SrHNT in CPC. For pre-osteoblast cells adding HNTs and SrHNTs to CPC help
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formation of acidic mucopolysaccharides. There was an overall increase for a period of 7
days and then 10% HNT and SrHNT in CPC showed the maximum absorbance on Day
21. One-way Anova showed no significance difference between the groups. Adding
SrHNT provided the signal generation to the cells to produce more acidic
mucopolysaccharides. Formation of acidic mucopolysaccharide is very essential for bone
implants as it serves as a lubricant and increase elasticity to connective tissue. It is an
essential part of ligament and cartilage. It plays an important role in motor functions,
reduction of inflammation, and helps support the bone growth. It is also essential for the
breakdown of excessive mucopolysaccharides as it can result in medical condition called
mucopolysaccharidoses which can affect the cartilage and bones. The decline seen in the
amount after 14 days is beneficial for break down or removal.
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Figure 6-18 A: Alcian blue staining of mouse stromal cells for a period of 28 days with
all the four groups (40 mg). n=5, Error bars=Standard Deviation
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Figure 6-18 B: Alcian blue staining of pre-osteoblast cells for a period of 21 days with
all the four groups (40 mg). n=5, Error bars=Standard Deviation
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6.2.5

ALPase Assay
This test was conducted to evaluate the osteogenic lineage of stromal stem cells

and pre-osteoblast cells when SrHNT was added to them. Addition of an external sample
should not change the lineage or signal the cells towards other differentiation which is not
bone or bone related. Figure 6-19 A (mouse stromal cells) and Figure 6-19 B (preosteoblast cells) show the graphical representation of ALPase assay where higher
absorbance meant presence of more cells showing osteogenic lineage. For the stromal
cells there is a general increase over 14 days and then there is a gradual decrease in
absorbance. This can be due to the further differentiation of cells to osteoblast cells. Oneway Anova showed a significant difference of 5% HNT and SrHNT in CPC, and 10%
SrHNT in CPC. In Figure 6-19 B the graph of pre-osteoblast cell showed that preosteoblast cells by default had the osteogenic lineage. Adding CPC and CPC embedded
with HNT and SrHNT added to their lineage potential. Although there was a clear trend
of increase in 7 days and then a decrease for SrHNT embedded CPC. Adding HNTs
showed a higher absorbance in 7 and 14 days. One-way Anova showed no significant
difference among the groups. Adding HNTs, SrCO3, and SrHNTs increased the
mechanical stimulation required for the cells so they could experience the change in their
architecture to promote their differentiation towards osteoblast cells. As the bone implant
degrades, it is important for cells to differentiate into bone cells so they can replace the
biodegradable implants.
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Figure 6-19 A: ALPase assay of mouse stromal cells for a period of 28 days with all the
four groups (40 mg). n=5, Error bars=Standard Deviation
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Figure 6-19 B: ALPase assay of pre-osteoblast cells for a period of 21 days with all the
four groups (40 mg). n=5, Error bars=Standard Deviation
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6.2.6

Picosirus Stain
PSR stain was used to evaluate the collagen content of the well after the addition

of the four groups and compare the difference among them. Under in-vitro condition
growth factors can stimulate the differentiation of stromal stem cells to type 1 collagen
and osteogenic marker genes. Collagen provides structure and strength to the bones.
Figure 6-20 A (mouse stromal cells) and Figure 6-20 B (pre-osteoblast cells) show the
graphical representation of PSR stain where higher absorbance meant presence of more
collagen. Collagen content was an overall high on day 7. For stromal cell the wells
having 5% SrHNT in CPC showed the highest collagen content on day 7 and was
significantly different from other groups when one-way Anova was calculated. For preosteoblast cells 1% SrHNT in CPC showed the highest collagen content on day 7 and
overall. There was no significant difference among the groups and samples. Addition of
SrHNT in CPC increased the formation of collagen over 21 days. High collagen content
is important as it prevents bone loss and relieve pain in the joints.
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Figure 6-20 A: PSR stain of mouse stromal cells for a period of 28 days with all the four
groups (40 mg). n=5, Error bars=Standard Deviation
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Figure 6-20 B: PSR stain of pre-osteoblast cells for a period of 21 days with all the four
groups (40 mg). n=5, Error bars=Standard Deviation.

6.2.7

Alizarin Red Stain
This stain was done on pre-osteoblast cells with the four groups of samples for a

period of 28 days and compared to a commercially available product. This stain was done
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to evaluate the impact of Sr in production of Ca by pre-osteoblast cells. The images taken
through a fluorescence microscope is observed in Figures 6-21 A (day 7), B (day 14), C
(day 21), and D (day 28) respectively. Alizarin red highlights the calcium deposits in red.
There is overall increase in calcium deposit by day 21. The commercial product is seen to
have less calcium compared to SrHNT 1% in CPC on day 7. Alizarin red deposits are not
seen in abundance on day 28. This can be due to high acidic nature of the stain which
tends to remove the cells and contents of the well during the washes. On day 28 HNT 1%
and 5% in CPC showed a lot of red staining showing a high calcium content 1% SrHNT
showed purple color stain showing calcium compounds. Since these images could not be
diagnosed through ImageJ, no numerical value could be added to the content of Ca.

Figure 6-21 A: Alizarin red stain of pre-osteoblast cells for day 7 with all the four groups
and a commercially available CPC (40 mg).
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Figure 6-21 B: Alizarin red stain of pre-osteoblast cells for day 14 with all the four
groups (40 mg).

Figure 6-21 C: Alizarin red stain of pre-osteoblast cells for day 21 with all the four
groups (40 mg).
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Figure 6-21 D: Alizarin red stain of pre-osteoblast cells for day 14 with all the four
groups and a commercially available CPC (40 mg).

6.2.8

Surface Topography
SEM images were taken to analyze the surface topography of all the groups of

CPC. Since cell viability and proliferation mainly depend on the surface of the substrate.
Rougher the surface higher the probability for cell attachment and cell viability Figures
6-22 A (CPC and Group 2), B (CPC and Group 3), and C (CPC and Group 4) show the
SEM images. As seen in the images CPC has comparatively very smooth surface. Adding
HNTs, SrCO3, and SrHNT introduced a more granular and porous surface. Higher the
pore density higher the surface available for cell attachment. This distribution of HNTs
and SrHNTs as seen in all the images can help in increasing the mechanical strength and
prevent crack propagation in implants or filling when CPC is used.
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Figure 6-22 A: SEM images of CPC and Group 2 samples with 1% HNT, SrCO3, and
SrHNT in CPC. The top and bottom layer images were taken at 100 µm and 40 µm
respectively.

Figure 6-22 B: SEM images of CPC and Group 3 samples with 5% HNT, SrCO3, and
SrHNT in CPC. The top and bottom layer images were taken at 100 µm and 40 µm
respectively.
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Figure 6-22 C: SEM images of CPC and Group 4 samples with 10% HNT, SrCO3, and
SrHNT in CPC. The top and bottom layer images were taken at 100 µm and 40 µm
respectively.

6.2.9

Multi BET
BET pore size was done with helium adsorption-desorption method. This

evaluation helped asses the differences in pore size after the addition of HNTs and
SrHNT. Figure 6-23 shows the graph of pore size based on the average of 1gm of 2
different samples size. The third data was taken for 200 mg and was considered too small
an amount to give accurate results and hence was not used for graphical representation.
As seen in the graph addition of 10% of HNT and SrHNT showed an increase in pore
radius compared to plain CPC. Larger the pore sizes more surface is available for cell to
adhere.
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Figure 6-23: Shows the average pore radius of all the groups measured by NOVA e2000
surface are and pore analyzer. N=2 and error bars are Standard deviation.

6.2.10

Compression Strength
Compression test was done to analyze the maximum compressive strength and the

peak load taken by the materials from all the 4 groups before they fractured. Figure 6-24
shows the graphical representation of the peak load taken by the samples. Samples with
5% HNT and SrHNT in CPC showed high compression strength, highest in CPCs with
5% SrHNT. CPCs with 10% SrCO3 also showed high compression strength. SrHNT 5%
in CPC shows the combined properties of HNT and SrCO3 and hence has a strong peak at
100 Mpa. Over all the addition of HNTs, SrCO3, and SrHNT improved the load bearing
strength of CPC. Human bones have a high compression strength of 180 -150 Mpa based
on the nature of their formations which slowly decreases with age. This result showed
that of all the compositions tested, 5% SrHNT in CPC showed a much higher
improvement especially compared to plain CPC. One-way Anova calculated showed
significant differences among all the groups with highest value of difference in 5%
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SrHNT in CPC. Further testing needs to be conducted to find the right ration of SrHNT in
CPC to reach the strength of human bones.
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Figure 6-24: Peak compression strength of all the groups. The error bars are standard
deviation where n=5, Error bars=Standard Deviation.

6.2.11

Flexural Strength
A three-point bend test was performed to get the estimate of the flexural strength

of all the groups. This test evaluates the maximum force to bend the materials before it
breaks. Figure 6-25 shows the graphical representation of the peak flexural strength of all
the samples in the four groups. Human bones have a fracture toughness of 4 MPa.
Overall samples showed a high flexural strength After the addition of HNT 10% and
SrHNT 1% to the CPCs, it showed the highest flexural strength of 13.1 and 13.3 MPa
respectively. This may be due to the binding of CPC with chitosan was affected by
SrHNT. Higher the SrHNT in the sample less binding of the particles on a larger surface
area resulting in low bending threshold. One-way Anova showed a significant difference
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for all the groups with highest difference of 1% SrHNT in CPC. Adding HNTs and
SrHNTs improved the flexural strength of the cement and hence increasing the fracture
toughness of the samples.
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Figure 6-25: graphical representation of the peak flexural strength of all the groups.
Error bars are the standard deviation where n=3, Error bars=Standard Deviation.

6.2.12

Anti-Bacterial Property
To measure the bactericidal properties of all the groups, 5mm x 2mm discs for all

the groups were made and place on the petri dish with Mueller Hilton agar and two
separate lawns of E. coli (Figure 6-26 A) and S. aureus (Figure 6-26 B) representing a
gram-negative and a gram-positive bacterium respectively. Zones of inhibition were
measured for all the samples and graph was made based on the area of inhibition for all
the groups as seen in Figure 6-27 A for E. coli and Figure 6-27 B for S. aureus. CPC by
nature did not show any bactericidal properties. Although the zones of inhibition of
gentamicin discs were the maximum, all the groups showed anti-bacterial property
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inhibiting the growth of both gram positive and negative bacteria. One-way Anova
showed np significant difference among the groups. SrHNT in CPC discs showed the
highest zone of inhibitions. Sr by inherent nature has antibacterial properties which
showed effect in these discs. Implants with SrHNT will have lower the infections around
the implants.

A

B

Figure 6-26: Image showing the petri dishes with the discs over lawns of A) E. coli and
B) S. aureus. The experiment was done in triplicate from cultures of 3 different colonies
of bacteria.
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Figure 6-27 A: Graphical representation of the zones of inhibition measured in mm for
all the groups for E. coli. Error bars are standard deviation where n=3.
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Figure 6-27 B: Graphical representation of the zones of inhibition measured in mm for
all the groups for S. aureus. Error bars are standard deviation where n=3.

6.2.13

Biodegradability
It is an important property of CPC implants to dissolve slowly after a period of

time an allow for the bones cells to grow the affected part again. To evaluate the
degradability of the all the 4 groups 5 mm in diameter x 2mm in thickness discs were
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place in 1 ml of SBF for six weeks till when the weight of the samples started to lower
and the samples started to disintegrate. The weight of the samples was taken as dry
weight and dipped in SBF and measured for wet weight on day zero. After which the
samples were taken and blotted off the excess water and measured every seven days. The
values of triplicate of triplicate samples was plotted in the graphs as seen in Figures 6.28
A (CPC and Group 2), B (CPC and Group 3), and C (CPC and Group 4). The weights of
the discs increased over a period of 1 week and stayed around at that weight till week 4
before it started to decrease in weight and started to disintegrate. This test was done in
SBF which had a pH of 7.4 matching the body fluid pH and ion concentration of a normal
healthy human body. The pH of different systems is different and pH near the injury or
cancerous region in the body is acidic. Further testing needs to be done to test for the
biodegradability in different acidic and basic pH fluids.
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Figure 6-28 A: Graphical representation of degradability of CPC and group 2 over 6
weeks. Error bars are standard deviation where n=3x3.
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Figure 6-28 B: Graphical representation of degradability of CPC and group 3 over 6
weeks. Error bars are standard deviation where n=3x3.

10%

60

Weight in mg

50
40
30
20
CPC
HNT 10%
SrCO3 10%
SrHNT 10

10
0
Dry
D42

Wet

D7

D14

D21

D28

D35

Every 7 Days

Figure 6-28 C: Graphical representation of degradability of CPC and group 4 over 6
weeks. Error bars are standard deviation where n=3x3.
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6.3 Project 3: Using SrHNT as a Drug Carrier
6.3.1

SEM
The method of coating SrHNT involved hydrolysis of Sr2+ ions in water and then

forming a bond with the hydroxyl ion on the surface of HNT. it was important to evaluate
the retainment of Sr coating on HNTs after they were immersed in liquid phase of drugs
used for vacuum loading. SEM images were taken of SrHNT after drug loading as seen in
Figure 6-29. The images showed that the SrHNT retained the coating after drug loading
also. HNTSr were samples where the loading was followed by coating of Sr. As seen in
the SEM images the Sr coating was successful after loading the HNTs with drugs.

Figure 6-29: SEM images of gentamicin loaded HNT, HNTSr, and SrHNTs.

6.3.2

Gentamicin

6.3.2.1

Live Dead Assay
The HNTs SrHNTs and HNTSr is loaded with any drug, it is important to

evaluate the right concentration of the particular antibiotic and loaded nanoparticle
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combination which will not affect the cell viability. Cells used for this test was preosteoblast cells. A live dead assay was conducted for three different concentrations of
1 mg/ml, 0.1 mg/ml, and 0.01 mg/ml for day 1 (Figure 6-30 A and B for live and dead),
day 3 (Figure 6-31 A and B for live and dead), and day 7 (Figure 6-32 A and B for live
and dead) to narrow down the right concentration for suitable cell viability. As seen in
the image high concentrations of all the three nanoparticles were not conducive for cell
viability. Even on day 1 there is a low concentration of green cells for 1 mg/ml and
0.1 mg/ml. Although they did not appear to have a toxic effect as the red dead cells are
very few. By day seven the live green cells for both the higher concentrations is very low
but the cells thrived in 0.01 mg/ml with loaded nanoparticles. This experiment showed
that the drug loaded HNTs, SrHNTs, and HNTSr would not have a negative impact of
cell viability in low concentrations.

Figure 6-30 A: Live dead cell assay where the live cells are seen in green for 3 different
concentrations of HNT, HNTSr, and SrHNT for day 1.
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Figure 6-30 B: Live dead cell assay where the dead cells are seen in red for 3 different
concentrations of HNT, HNTSr, and SrHNT for day 1.

Figure 6-31 A: Live dead cell assay where the live cells are seen in green for 3 different
concentrations of HNT, HNTSr, and SrHNT for day 3.
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Figure 6-31 B: Live dead cell assay where the dead cells are seen in red for 3 different
concentrations of HNT, HNTSr, and SrHNT for day 3.

Figure 6-32 A: Live dead cell assay where the live cells are seen in green for 3 different
concentrations of HNT, HNTSr, and SrHNT for day 7.
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Figure 6-32 B: Live dead cell assay where the dead cells are seen in red for 3 different
concentrations of HNT, HNTSr, and SrHNT for day 7.

Image J was used to quantitatively analyze the live dead assay and was
graphically represent in Figures 6-33 A (1 mg/ml), B (0.1 mg/ml), and C (0.01 mg/ml).
As the graphs show the cell viability count on day seven was highest for 0.01 mg/ml.
Overall SrHNT showed better cell viability in all the concentration. Coating HNTs with
Sr may provide a layer that effects the cells in a positive manner. One-way Anova
showed no significant difference between the samples in same concentrations.
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Figure 6-33 A: Graphical representation of Live dead cell assay of HNT, HNTSr, and
SrHNT for 1 mg/ml for day 1, 3, and 7 where n=3, error bars are Standard deviation.
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Figure 6-33 B: Graphical representation of Live dead cell assay of HNT, HNTSr, and
SrHNT for 0.1 mg/ml for day 1, 3, and 7 where n=3, error bars are Standard deviation.
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Figure 6-33 C: Graphical representation of Live dead cell assay of HNT, HNTSr, and
SrHNT for 0.01 mg/ml for day 1, 3, and 7 where n=3, error bars are Standard deviation.

6.3.2.2

Disk Diffusion Method for CPC
This test was done to evaluate the successful release of drugs from drug loaded

SrHNT and HNTSr when they are embedded in CPC in different percentages by weight.
The same percentages were used as in project 2. The discs of CPC were made as 6mm
diameter x 2mm thickness and place in lawns of E. coli and S. aureus in Mueller Hilton
plates as seen in Figure 6-34 A and the control was the ready gentamicin discs and to test
for the viability of the bacteria plates with just the lawn of the bacteria was made as seen
in Figure 6-34 B. The bactericidal effect of the drugs released through these discs was
measured by the diameter of zone of inhibition. A clear are around the disks showed that
gentamicin was released to kill the bacteria around the discs containing gentamicin
loaded HNT, SrHNT, and HNTSr, in different percentages. The graphical representation
of the zones of inhibition created by drug loaded HNT, SrHNT, and HNTSr was plated as
seen in Figure 6-35 A (E. coli) and B (S. aureus). One-way Anova shows no significant
different among the samples and gentamicin discs. The graphs show that the drug was
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effectively release through the nanoparticles and CPC. The overall zone of inhibitions
was slightly more that caused by standard gentamicin discs. This can be explained as the
SrHNTs and HNTSr have inherent antibiotic properties. This test showed that drug
loaded SrHNTs can be embedded in CPC implants.

Figure 6-34 A: Disk diffusion plates with discs of 1%, 5%, and 10% HNT, SrHNT, and
HNTSr individually in CPC for E. coli and S. aureus.

Figure 6-34 B: Disk diffusion plates with and without gentamicin disc in E. coli and S.
aureus lawn.
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Figure 6-35 A: Graphical representation of zone of inhibition of gentamicin discs, and
CPC discs with 1%, 5%, and 10% of HNT, SrHNT, and HNTSr individually in lawns of
E. coli. The error bars are standard deviations where n=3.
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Figure 6-35 B: Graphical representation of zone of inhibition of gentamicin discs, and
CPC discs with 1%, 5%, and 10% of HNT, SrHNT, and HNTSr individually in lawns of
S. aureus. The error bars are standard deviations where n=3.
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6.3.2.3

Drug Loaded Nanoparticles in a Contaminated Cell Environment
The release and effectiveness of gentamicin loaded SrHNT and HNTSr was tested

in a cell environment using pre-osteoblast cells with the addition of E. coli bacteria. After
inoculating the cells with the bacteria live dead assay was performed after 24 hours to
visualize the health of the pre-osteoblast cells. The images were taken as seen in Figures
6-36 A (live cells) and B (dead cells), for pre-osteoblast cells (POB), POB with
gentamicin (AB), POB with AB and E. coli, just E. coli, POB with E. coli and the three
loaded HNTs, SrHNT, and HNTSr individually. As seen in the images, POB are able to
survive even after the contamination with bacteria and addition of AB reduces the
blurriness of the images caused by bacterial growth. Clear cells are seen in the images of
HNT, SrHNT, and HNTSr indicating the release of gentamicin which was bactericidal.
The presence of E. coli caused a higher cell death seen in red in the images of dead cells
after 24 hours.
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Figure 6-36 A: Images from Live and dead assay where live cells are seen in green. The
images show pre-osteoblast cells (POB), POB with gentamicin (AB), POB with AB and
E. coli, just E. coli, POB with E. coli and the three loaded HNTs, SrHNT, and HNTSr
individually after 24 hours.

Figure 6-36 B: Images from Live and dead assay where dead cells are seen in red. The
images show pre-osteoblast cells (POB), POB with gentamicin (AB), POB with AB and
E. coli, just E. coli, POB with E. coli and the three loaded HNTs, SrHNT, and HNTSr
individually after 24 hours.
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6.3.2.4

Bacterial Growth
To access the rate of bacterial growth, optical density was measured for the

multiple 48 well plates with the samples before addition of bacteria, after addition of
samples as Time 0, and after 24 hours from the time bacteria was inoculated as T 24 and
plotted in a graph as seen in Figure 6-37. As the graph shows the bacterial growth was
unhindered and showed highest absorbance in the wells containing just the bacteria and
POB with bacteria. The bacterial growth rate was stopped by gentamicin release in the
well having 0.01 mg/ml of HNTs, SrHNT, and HNTSr. This graph showed that AB
loaded SrHNT and HNTSr released the drugs effectively and the caps of the halloysites
was not closed due to Sr coatings. This also went on to show that SrHNTs and HNTSr
can be effectively loaded with this AB and be embedded in these particular cells at a
concentration of 0.01 mg/ml and be effective. Further tests have to be conducted to
ensure that Sr coated HNTs will be effective with multiple drugs and various cell lines.
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Figure 6-37: Graphical representation of pre-osteoblast cells (POB), POB with
gentamicin (AB), POB with AB and E. coli, just E. coli, POB with E. coli and he three
loaded HNTs, SrHNT, and HNTSr individually. * shows the reading before addition of
Bacteria, * shows Time 0 after adding E. coli, and * shows the readings at time 24. n=6

6.3.2.5

Proliferation Assay
Proliferation assay was conducted to analyze if the POB proliferated with bacteria

and AB and the drug loaded SrHNTs and HNTSr with the same rate as control cells. This
test was to evaluate the effectiveness of drug release by the nanoparticles which was
bactericidal, and at the same time would not impact the POB to proliferate. The
proliferation rate was represented in a graph as seen in Figure 6-38. As seen in the graph
the cells showed a higher absorbance when the bacteria were present in the wells which
was due to the presence of bacteria. One -way Anova showed no significant difference
between the wells. The cells with the nanoparticle showed normal proliferation rate but
higher absorbance then just pre-osteoblast which may be due to the presence of the cell
debris.
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Figure 6-38: Graphical representation of the proliferation assay of pre-osteoblast cells
(POB), POB with gentamicin (AB), POB with AB and E. coli, just E. coli, POB with E.
coli and he three loaded HNTs, SrHNT, and HNTSr individually. n=6. Error bars are
Standard deviation.

6.3.3

Methotrexate Loading

6.3.3.1

Live Dead Assay
Methotrexate is used as a chemotherepautic agent. The combination with SrHNT

and HNTSr was studied to evaluate the right concentration which will not affect the cell
viability. Cells used for this test pre-osteoblast cells. A live dead assay was conducted
for three different concentration 1 mg/ml, 0.1 mg/ml, and 0.01 mg/ml for day 1 (Figures
6-39 A and B for live and dead), day 3 (Figures 6-40 A and B for live and dead), and day
7 (Figure 6-41 A and B for live and dead)to narrow down the right concentration for
suitable cell viability. As seen in the image high concentrations of all the three
nanoparticles reduced the live cells. Even on day 1 there is a low concentration of green
cells for 1 mg/ml and 0.1 mg/ml. Although they did not appear to have a toxic effect as
the red dead cells are very few. By day seven the live green cells for both the higher
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concentrations is very low but the cells thrived in 0.01 mg/ml with loaded nanoparticles.
This experiment showed that 0.01 mg/ml methotrexate loaded HNTs, SrHNTs, and
HNTSr would not have a negative impact of cell viability in low concentrations.

Figure 6-39 A: Live dead cell assay where the live cells are seen in green for 3 different
concentrations of HNT, HNTSr, and SrHNT for day 1.

Figure 6-39 B: Live dead cell assay where the dead cells are seen in red for 3 different
concentrations of HNT, HNTSr, and SrHNT for day 1.
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Figure 6-40 A: Live dead cell assay where the live cells are seen in green for 3 different
concentrations of HNT, HNTSr, and SrHNT for day 3.

Figure 6-40 B: Live dead cell assay where the dead cells are seen in red for 3 different
concentrations of HNT, HNTSr, and SrHNT for day 3.
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Figure 6-41 A: Live dead cell assay where the live cells are seen in green for 3 different
concentrations of HNT, HNTSr, and SrHNT for day 7.

Figure 6-41 B: Live dead cell assay where the dead cells are seen in red for 3 different
concentrations of HNT, HNTSr, and SrHNT for day 7.

Image J was used to quantitatively analyze the live dead assay and was
graphically represent in Figures 6-42 A (1 mg/ml), B (0.1 mg/ml), and C (0.01 mg/ml).
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As the graphs show the cell viability count on day three was highest for
0.01 mg/ml among all the concentrations. The control cells showed a decrease in growth
by day 3 and then the cell showed increase in the live count by day 7. This can be
explained that the drug methotrexate is light sensitive and hence the plates were wrapped
in an aluminum foil when incubated. The cells may have taken a few days to get
acclimatized to the environment. Overall SrHNT showed better cell viability in all the
concentration. Coating HNTs with Sr may provide a layer that effects the cells in a
positive manner. One-way Anova showed no significant difference between the samples.
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Figure 6-42 A: Graphical representation of Live dead cell assay of HNT, HNTSr, and
SrHNT for 1 mg/ml for day 1, 3, and 7 where n=3 and error bars are Standard deviation.
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Figure 6-42 B: Graphical representation of Live dead cell assay of HNT, HNTSr, and
SrHNT for 0.1 mg/ml for day 1, 3, and 7 where n=3 and error bars are Standard
deviation.
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Figure 6-42 C: Graphical representation of Live dead cell assay of HNT, HNTSr, and
SrHNT for 0.01 mg/ml for day 1, 3, and 7 where n=3 and error bars are Standard
deviation.

6.3.3.2

Drug Loaded Nanoparticles in CRL 2836 Cell
The release and effectiveness of methotrexate loaded SrHNT and HNTSr was

tests in a cell environment (mouse bone cancer cells). After inoculating the cells with the
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bacteria live dead assay was performed on day 1 and day 3 to visualize the effectiveness
of drug release and cell death. The images were taken as seen in Figure 6-43 A (live
cells), and B (dead cells) with osteosarcoma cells, cells with methotrexate, and cells with
the three loaded HNTs, SrHNT, and HNTSr individually. As seen in the images, cancer
cells are only able to survive when there is no methotrexate or drug loaded nanoparticles.
The presence of methotrexate loaded HNT, SrHNT, and HNTSr caused a higher cell
death seen in red in the images of dead cells after 3 days. The live cells were also lower
after day three.

Figure 6-43 A: Live dead assay where the live osteosarcoma cells are seen in green for
day 1 and 3.
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Figure 6-43 B: Live dead assay where the dead osteosarcoma cells are seen in red for
day 1 and 3.

6.3.3.3

Proliferation Assay for Osteosarcoma Cells
To evaluate the effectiveness of drug release from the nanoparticle’s proliferation

assay was conducted. In case of osteosarcoma cells, where lower the cell proliferation
higher the expectancy from the SrHNTs and HNTSr to be successful in releasing
chemotherapeutic drugs on the cancerous sites. This drug loaded nanoparticles can also
be embedded in bone implants where the bone is replaced due to cancer. The cell
proliferation was plotted in a graph as seen in Figure 6-44. The proliferation assay
shows that osteosarcoma cells have an increasing rate of proliferation on day and day 7.
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Figure 6-44: Graphical representation of the osteosarcoma cell proliferation assay for
day 1, 3, and 7. Error bars are Standard deviation. n=5.

Adding methotrexate directly and through loaded HNTs, SrHNTs, and HNTSr
reduced the rate of proliferation on day 3 and the rate was lower on day 7 when compared
to just cells. This can be explained due to the media change every 2 days that can be the
cause of removal of the drugs released and present in the wells. Overall methotrexate
loaded SrHNT and HNTSr released the drug and resulted in osteosarcoma cell death.

CHAPTER 7
CONCLUSIONS AND FUTURE WORK

Projects 1, 2, and 3 discussed the tests and results of interrelated concepts and
novel applications of green SrHNTs in CPC and as drug carriers. This chapter synthesizes
the recorded observations and integrates them. Plan for future direction of this work is
also provided.

7.1 Sr Coating on HNTs
Project 1 discussed in detail the successful coatings of HNT with Sr in testing of
hypothesis that Sr can be coated on HNTs without the use of harsh chemical and
producing any toxic waste. The observations from the results showed that the coating was
successful. Live dead assay gave the appropriate quantities that could be applied to
SrHNT to good cell viability. SrHNT was beneficial for cell proliferation in preosteoblast
cells Micro-titration testing with nosocomial bacteria showed that and in limited
quantities were beneficial for drug release and had inherent antibacterial properties. For
future studies SrHNTs cell viability needs to tested in multiple cells lines. These studies
will reveal the effectiveness of the SrHNT in various cell environments. The behavior of
SrHNT and the pattern of proliferation can modify the utilization of SrHNTs in the body.
This information can also provide information for further use of SrHNT in three
dimensional constructs and implants.
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7.2 Project 2: Embedding SrHNT in CPC for Bone Regeneration
Project 2 discussed in detail the tests conducted when SrHNT was embedded in
different concentrations in CPC paste. The cell viability and proliferation tests showed
that introducing SrHNT in CPC only enhanced the richness of cellular environment.
Various histological staining for stromal cells and preosteoblast cells showed the addition
of SrHNT increased Ca, acidic mucopolysaccharides production and the mechanical
stress required for cells to increase the osteogenic lineage increased. Further tests have to
be done to confirm the efficiency of SrHNTs in other cell lines. Disc diffusion analysis
showed that CPCs with SrHNT had inherent antibacterial properties. The hypothesis that
coating HNT with Sr will increase the compression and mechanical strength of CPC was
accepted since the compression testing showed 5 times increase in mechanical strength
when compared to plain CPC. Compression strength was maximum for 10% SrHNT in
CPC and mechanical strength showed the maximum at 1% SrHNT in CPC. Further tests
needs to be done to find the correct weight ratios of SrHNT and CPC so that the bone
implant mimics the stress load it can take to that of natural human bones. SrHNTs in CPC
caused prominent changes in the surface properties of CPC. Upon addition of SrHNT the
surface was significantly modified which promotes better cell attachment and viability.
Drug release from doped SrHNT and HNTSr was studied for 24 hours. Clear zones of
inhibition were observed in E. coli and S. aureus cultures. Three-dimensional printed
bone implants should have the capacity to encourage cell growth, increase the production
of bone cells, have high compression strength to bear loads, and also prevent infection on
the site of the implant. These implants should be biodegradable so that the bone cells can
grow and overtake the implant material. Further tests need to be done to confirm the rate
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of biodegradability in different Ph environment. Embedding drug loaded SrHNTs in the
CPC paste used for printing the bone scaffolds is seen to have all those properties based
on the results obtained so far.

7.3 Project 3: Using SrHNT as a Drug Carrier
Project 3 showed test and results in regards to the practical applications of drug
loaded SrHNT and HNTSr in an infected cell environment and a cancerous cell
environment. Two drugs gentamicin and methotrexate were loaded in SrHNT and
HNTSr. The third hypothesis that the SrHNT will act a good drug carrier was accepted
based on the results of tests done in this project. The drug release was tested in a cell
environment contaminated with a nosocomial bacterial culture. SrHNT and HNTSr both
effectively reduced the bacterial growth and showed no decrease in cell proliferation. The
second test was done with a chemo drug loaded SrHNT and HNTSr and introduced to
cancer cells. The test results showed that drug was effectively released and caused
reduction in cell viability. Further tests have to be done with various other drugs. The
drugs also should be tested in multiple cell environment.
Since new methods are needed for a more patient specific needs in the areas of
bone grafts and drug delivery can use the product and concept from this research.
SrHNTs can be used in 3D printed grafts and can be seeded with cells. These grafts can
be used in patients to create a living graft. SrHNTs in various field has a great potential
for bone and tissue engineering.
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